# Valuing Life as an Asset, as a Statistic and at $\mbox{Gunpoint}^1$

Julien Hugonnier<sup>1,4,5</sup>, Florian Pelgrin<sup>2,6</sup> and Pascal St-Amour<sup>3,4,6</sup>

<sup>1</sup>École Polytechnique Fédérale de Lausanne <sup>2</sup>EDHEC Business School

<sup>3</sup>University of Lausanne, Faculty of Business and Economics (HEC)

<sup>4</sup>Swiss Finance Institute

 $^{5}\mathrm{CEPR}$ 

<sup>6</sup>CIRANO

April 4, 2018

<sup>1</sup>Financial support by the Swiss Finance Institute is gratefully acknowledged. We have benefited from very useful discussions with and comments from Georges Dionne, Pierre-Carl Michaud, Michel Normandin and Mathias Thoenig. The usual disclaimer applies.

#### Abstract

The Human Capital (HK) and Statistical Life Values (VSL) differ sharply in their empirical pricing of a human life and lack a common theoretical background to justify these differences. We first contribute to the theory and measurement of life value by providing a unified framework to formally define and relate the Hicksian willingness to pay (WTP) to avoid changes in death risks, the HK and the VSL. Second, we use this setting to introduce an alternative life value calculated at Gunpoint (GPV), i.e. the WTP to avoid certain, instantaneous death. Third, we associate a flexible human capital model to the common framework to characterize the WTP and the three life valuations in closed-form. Fourth, our structural estimates of these solutions yield mean life values of 8.35 M\$ (VSL), 421 K\$ (HK) and 447 K\$ (GPV). We confirm that the strong curvature of the WTP and the linear projection hypothesis of the VSL explain why the latter is much larger than other values.

**Keywords**: Value of Human Life, Human Capital, Value of Statistical Life, Hicksian Willingness to Pay, Equivalent Variation, Mortality, Structural Estimation.

JEL Classification: J17, D15, G11.

# 1 Introduction

### 1.1 Motivation and outline

Evaluating the price of a human life has long generated a deep interest in economic research.<sup>1</sup> Indeed, life valuations are often relied upon in public health and safety debates, such as for cost/benefit analyses of life-saving measures in transportation, environmental, or medical settings. They are also important from a long-run perspective to determine whether to spend more resources on innovations that foster consumption growth or on those that prolong life expectancy.<sup>2</sup> Finally, economic life values are resorted to in occupational, or end-users' wrongful death litigation.

Three main sources of difficulty render the pricing of life particularly challenging. First, a human life is by definition non-divisible. This implies that any marginal valuation, e.g. through the wage compensation for workers' fatality risk exposure, must ultimately be integrated into a unitary life value. Second, a human life is non-marketed. The absence of equilibrium prices implies that the economic value of a human life must somehow be inferred from relevant and measurable proxies such as foregone income, or responses to changes in mortality risks. Finally, ethical considerations induce significant discomfort in computing – and eventually comparing – the life values of identified persons.

The two most widely-used life valuation frameworks differ in how these challenges are dealt with. The Human Capital (HK) approach does not balk at valuing the life of an identified person. Relying on standard asset pricing, the HK life value is the present value of the net cash flow associated with human capital, where the dividend is proxied by the marketed labor income, net of the measurable expenses required to maintain that capital. The Value of a Statistical Life (VSL), introduced by Drèze (1962) and Schelling (1968), relies on a stated, or inferred, willingness to pay (WTP) to avert (resp. attain) small increases (resp. reductions) in exposure to death risks. Under appropriate assumptions, a collective WTP to save one unidentified (i.e. statistical) life among the group can be

 $<sup>^{1}</sup>$ Landefeld and Seskin (1982) make reference to human-capital based evaluations of the value of life dating back to Petty (1691).

 $<sup>^{2}</sup>$ See Jones (2016); Hall and Jones (2007); Becker et al. (2005) for discussions.

recovered through a linear aggregation of the individual WTP's.<sup>3</sup> Focusing on the value of an unidentified, rather than personalized, life thus conveniently avoids the uncomfortable issues associated with computing and comparing the values of identified lives.

Both the HK and the VSL are pricing the same underlying object and should presumably come up with similar values. However, these two valuations yield strikingly different prices in practice with VSL estimates 10-20 times larger than HK values.<sup>4</sup> Rationalizing these differences is complicated by the absence of common theoretical underpinnings that encompass both valuations. Consequently, most HK and VSL evaluations are reducedform empirical exercises that never exploit joint theoretical restrictions and that are performed within disjoint data settings that further complicate comparisons.

This void between the two approaches leaves open a number of questions that we address in this paper. In particular, can a common theoretical and empirical framework help in rationalizing the differences between the HK and the VSL? Can this framework also yield a reasonable metric for the value of life against which the two alternatives can be gauged? More fundamentally, what lessons can we learn from an encompassing approach about the interpretation and applicability of the alternative measures in pricing the economic value of a human life?

To answer these questions, we first propose a unified theoretical background linking both the Human Capital and Statistical Life values. We start from a generic dynamic human capital problem in which an agent facing an uncertain horizon selects investment in his skills or his health, where human capital augments labor income. Assuming the existence of a solution to this problem satisfying weak preference for life over death, we use standard asset pricing to define the HK value as the discounted dividend stream, i.e. the income, net of investment, *along the optimal dynamic path*. We next rely on the associated indirect utility (i.e. the welfare at the optimum) which we combine with the Hicksian Equivalent Variation (EV, Hicks, 1946) to define the willingness to pay to avoid infra-marginal detrimental change in death risk exposure.<sup>5</sup> The theoretical VSL can then

<sup>&</sup>lt;sup>3</sup>As a canonical example (e.g. Aldy and Viscusi, 2007), suppose n agents are individually willing to pay  $v(\Delta)$  to attain (avert) a small beneficial (detrimental) change  $\Delta = 1/n$  in death risk exposure and satisfying v(0) = 0. The empirical VSL is the collective WTP:  $v_s^e(\Delta) = nv(\Delta) = v(\Delta)/\Delta$ , i.e. the slope of the WTP.

<sup>&</sup>lt;sup>4</sup>Huggett and Kaplan (2016) identify HK values between 300 K–900 K\$, whereas the U.S. Department of Transportation recommends using a VSL-type amount of 9.4 M\$ (U.S. Department of Transportation, 2016).

<sup>&</sup>lt;sup>5</sup>See also Becker et al. (2005) for willingness to pay for infra-marginal changes in death risk.

be derived formally in two equivalent ways: (i) as the (negative of the) marginal rate of substitution (MRS) between death exposure and wealth, calculated through the indirect utility and (ii) as the marginal WTP (MWTP) with respect to death risk, calculated through the EV. This encompassing setup ensures that the HK and the VSL are both evaluated from a common underlying dynamic problem and are thus directly comparable.

Second, we make use of this unified theoretical framework to define a *third* valuation alternative that forthrightly addresses the measurement challenges and can serve as a comparison benchmark. The objectives are to gauge the economic value of a human life without recourse to indirect proxies and/or arbitrary aggregation assumptions. Instead, we address the non-divisibility and non-marketability by resorting to the unitary shadow value of life accruing to its main beneficiary, i.e. the willingness to pay that leaves an agent indifferent between living and dying in a highwaymen threat. The Hicksian EV again provides a natural theoretical background to elicit this shadow value which we refer to as the Gunpoint Value of Life (GPV). To paraphrase Schelling (1968)'s seminal title, 'the life you save *is* your own' in our highwaymen threat valuation. Consequently, any discomfort in valuing someone else's life can be circumvented by having that person compute his *own* intrinsic value.

Third, we rely on a parametrized version of the encompassing human capital model to provide analytical calculations of the WTP, as well as of the Human Capital, Statistical Life and Gunpoint Values of life. This model is flexible enough to be applicable to either a skills (Ben-Porath, 1967; Heckman, 1976) or a health (Grossman, 1972; Ehrlich and Chuma, 1990) interpretation of human capital. It guarantees weak preference for life over death and yields closed-form solutions that allow us to compute the analytic expressions corresponding to the willingness to pay, as well as the three life values. We can therefore assess the contributions of fundamentals, such as preferences, risk distributions, or technology, as well as financial and human resources and thus investigate how the WTP, HK, VSL and GPV are theoretically related to one another.

Finally, we structurally estimate our parametrized model to provide closed-form estimates of the willingness to pay and the three alternative values of life from common theoretical and empirical frameworks. Towards that purpose, we associate human capital to health and adopt a revealed-preference perspective to estimate the model's distributional, technological and preferences parameters. This is achieved by resorting to PSID data that correspond to the optimal consumption, portfolio, as well as health spending and insurance policies. This procedure allows us to calculate the analytical expressions for the WTP, Human Capital, Statistical and Gunpoint Values of life. The HK and the VSL can be contrasted with reduced-form estimates, compared to one another, as well as with the estimated Gunpoint benchmark.

Our main findings are threefold. First, we innovate from the literature by showing that the Hicksian willingness to pay, Statistical, Human Capital and Gunpoint values of life *can* be jointly characterized and structurally estimated from a common dynamic human capital problem. Standard monotonicity and curvature properties of this problem – that are verified in our application and estimation – guarantee that the willingness to pay to avoid detrimental changes in exposure to death is increasing, concave and bounded in the mortality risk increment. It follows that the theoretical VSL (i.e. the marginal WTP) is under-estimated by the empirical VSL (the infra-marginal WTP over finite changes in death risk), and that both theoretical and empirical VSL's over-estimate the GPV (the WTP's upper bound). Importantly, we show that the ratio of the VSL to this limiting WTP is inversely proportional to the marginal propensity to consume (MPC). Since the MPC is typically much lower than one, the predicted VSL-GPV gap is positive and significant.

Secondly, unlike the VSL, both the HK and GPV directly compute the value of a whole life, rather than linearly projecting marginal threats to recover a unitary value. The Human Capital and Gunpoint values display further similarities in that both reflect expected net present values of human capital dividends (HK) and of consumption above subsistence (GPV), and both are independent of preferences towards risk and time. For HK, this independence reflects the market-based asset pricing of the dividends flow where the latter depends only on technological and distributional characteristics at the optimum. For the GPV, preference independence reflects the nature of mortality in a Gunpoint valuation; because death is instantaneous and certain under a highwaymen threat, attitudes towards time substitution and towards risks are irrelevant.

Third, our empirical results confirm that the willingness to pay is strongly concave and bounded above by the GPV. They also accord with the reduced-form HK and VSL estimates reported in the literature, with structural average values of 421 K\$ (HK) and 8.35 K\$ (VSL). Consequently, this large discrepancy between the HK and the VSL *cannot*  be explained by disjoint theoretical and empirical evaluations. Moreover, the average Human Capital value of life is close to the average Gunpoint benchmark (447 K\$), as expected from the theoretical parallels between the two. The large VSL/GPV ratio of 18.66 is consistent with a realistic MPC estimate of 5.36%.

The corroboration of large empirical VSL-HK differences, and the finding of HK-GPV similarities in an encompassing framework indicates that other reasons must be assessed to understand why the VSL yields much larger estimates. Towards that purpose, it is useful to revert to the original warnings by Schelling (1968) that the VSL should *not* be taken as a human life value, but rather as a collective willingness to avoid small changes in death risk.<sup>6</sup> We argue that the problem comes neither from that interpretation, nor from the approximations taken in the empirical literature to elicit it. Indeed, we formally show that the empirical VSL can be derived in closed form as a collective WTP and that the bias with the theoretical MWTP is small for small increments in death risk. The problem stems rather from the linear extrapolation from that marginal value to a unitary life value that is directly measured by the HK and GPV. The strong concavity of the WTP necessarily entails a significant approximation error from a linear projection to a holistic life value.

These findings also confirm early conjectures on the pitfalls associated with personalizing unidentified VSL life valuations. Indeed, Pratt and Zeckhauser (1996) argue that concentrating the costs and benefits of death risk reduction leads to two opposing effects on valuation. On the one hand, the *dead anyway* effect leads to higher payments on identified (i.e. small groups facing large risks), rather than statistical (i.e. large groups facing small risks) lives. In the limit, they contend that an individual might be willing to pay infinite amounts to save his own life from certain death. On the other hand, the wealth or *high payment* effect has an opposite impact. Since resources are limited, the marginal utility of wealth increases with each subsequent payment, thereby reducing

<sup>&</sup>lt;sup>6</sup>In his opening remarks, Schelling (1968, p. 113) writes

<sup>&</sup>quot;This is a treacherous topic and I must choose a nondescriptive title to avoid initial misunderstanding. It's not the worth of a human life that I shall discuss, but of 'life saving', of preventing death. And it's not a particular death, but a statistical death. What it is worth to reduce the probability of death – the statistical frequency of death – within some identifiable group of people, none of whom expects to die except eventually. "

the marginal WTP as mortality exposure increases.<sup>7</sup> Although the net effect remains uncertain, Pratt and Zeckhauser (1996, Fig. 2, p. 754) argue that the wealth effect is dominant for larger changes in death risk, i.e. for those cases that naturally extend to our highwaymen threat. Their conjecture is warranted in our calculations. We show that the willingness to pay is finite and bounded above by the Gunpoint Value. Diminishing MWTP entails that the latter is much lower than what can be inferred from the VSL.

The main take-away from this paper is therefore that the three life pricing approaches are relevant tools that should remain specialized in their respective applications. If society ends up paying for policies that result in small changes in death risk exposure affecting large populations, then the VSL is clearly appropriate, but its extrapolation to a human life value is not. In the latter case, the Human Capital and Gunpoint Values are better suited and applications such as wrongful death litigation or terminal care decisions should revert to the HK or GPV frameworks.<sup>8</sup>

After a review of the relevant literature in Section 1.2, the rest of the paper is organized as follows. We first introduce the formal links between the HK, WTP, VSL and GPV in Section 2. Sections 3 and 4 present the benchmark model and corresponding life values. The empirical strategy is discussed in Section 5, with structural parameters and values of life estimates reviewed in Section 6. We discuss and interpret these results in Section 7, with concluding remarks presented in Section 8.

#### **1.2** Related literature

#### 1.2.1 Human Capital values of life

The HK model associates the economic value of a person to the value of his human capital that is entirely depreciated at death. The latter is obtained by pricing the expected discounted stream of its associated dividends that are foregone upon death, i.e. the

<sup>&</sup>lt;sup>7</sup>Pratt and Zeckhauser (1996, p. 753) point out that whereas a community close to a toxic waste dump could collectively pay \$1 million to reduce the associated mortality risk by 10%, it is unlikely that a single person would be willing to pay that same amount when confronted with that entire risk.

 $<sup>^8\</sup>mathrm{For}$  example, Philipson et al. (2010, p. 2, emphasis added) contend that:

<sup>&</sup>quot;[...] living, like other goods, has diminishing marginal utility – the willingness to pay for an additional year of life falls with how many years one has to live. This is in contrast to how the value of a statistical life-year is taught and explained: it is often prefaced with claiming that it is not how much people are willing to pay to avoid having a gun put to their head (presumably one's wealth). However, terminal care decisions are often exactly of that nature."

lifetime labor income flows, net of associated investment.<sup>9</sup> Well-known issues related to this approach include the appropriate rate of discounting, the endogeneity of income and investment, as well as the treatment of non-labor activities.<sup>10</sup> As for HK models, we do calculate the net present value of the stream of human capital dividends that are lost upon death. Unlike HK models however, that value is computed in closed-form and relying on the stochastic discount factor induced by the assets under consideration in the model. In particular, we fully account for the endogeneity of the human capital stock and of its associated income and investment expenditures. We therefore encompass the relevant technological and distributional considerations, such as the capital production technology, its deterministic and stochastic depreciation, the income-capital gradient, as well as the duration of the dividends stream. Finally, the parametrized model is fully adaptable to non-labor valuation since the flow of marketed income related to human capital can also be equivalently recast as non-marketed utilitarian services (see Remark 1 below).

#### 1.2.2 Value of a Statistical Life

The empirical VSL alternative relies on explicit and implicit evaluations of the Hicksian WTP for a small reduction in fatality risk which is then linearly extrapolated to obtain the value of life. Explicit VSL uses stated preferences for mortality risk reductions obtained through surveys or lab experiments, whereas implicit VSL employs a revealed preference perspective in using decisions and outcomes involving fatality risks to indirectly elicit the Hicksian compensation.<sup>11</sup> Examples of the latter include responses to prices and fines in the use of life-saving measures such as smoke detectors, speed limitations, or seat belt regulations. The Hedonic Wage (HW) variant of the implicit VSL evaluates the equilibrium willingness to accept (WTA) compensation in wages for given increases in work dangerousness. Controlling for job/worker characteristics, the wage elasticity with respect to job fatality risk can be estimated and again extrapolated linearly to obtain the VSL (e.g. Aldy and Viscusi, 2008; Shogren and Stamland, 2002).

<sup>&</sup>lt;sup>9</sup>See Jena et al. (2009); Huggett and Kaplan (2013, 2016) for applications.

 $<sup>^{10}</sup>$ Conley (1976) provides additional discussion of HK approaches while Huggett and Kaplan (2016) address the discounting issues.

<sup>&</sup>lt;sup>11</sup>A special issue directed by Viscusi (2010) reviews recent findings on VSL heterogeneity. A meta analysis of the implicit VSL is presented in Bellavance et al. (2009). See also Doucouliagos et al. (2014) for a *meta*-meta analysis of the stated- and revealed-preferences valuations of life.

Hall and Jones (2007) propose a semi-structural measure of life value akin to the VSL. They adopt a marginal value perspective by equating the latter to the marginal cost of saving a human life. The cost of reducing mortality risk can be imputed by specifying and estimating a health production function and by linking health status to death risks. Dividing this marginal cost by the change in death risk amount yields a VSL-inspired life value, e.g. corresponding to 1.9 M\$ for an individual aged 40-44 (Hall and Jones, 2007, Tab. 1, p. 60). Unlike Hall and Jones (2007) we do not measure the health production function through its effects on mortality, but estimate the technology through the measurable effects of investment on future health status.<sup>12</sup> Moreover, our fully structural approach does not indirectly evaluate the marginal value of life via its marginal cost, but rather directly through the individual willingness to pay to avoid changes in death risks.

Ashenfelter (2006) provides a critical assessment of the VSL's theoretical and empirical underpinnings. He argues that the assumed exogeneity of the change in fatality risk can be problematic. For instance, safer roads will likely result in faster driving, which will in turn increase the number of fatalities. He also argues that agency problems might arise and lead to overvaluation in cost-benefit analysis when the costs of safety measures are borne by groups other than those who benefit (see also Sunstein, 2013; Hammitt and Treich, 2007, for agency issues). Ashenfelter further contends that it is unclear whose preferences are involved in the risk/income tradeoff and how well these arbitrage are understood. For example, if high fatality risk employment attracts workers with low risk aversion and/or high discount rates, then generalizing the wages risk gradient to the entire population could understate the true value of life. An argument related to Ashenfelter's preferences indeterminacy can be made for the HW variant of the VSL. Because wages are an equilibrium outcome, they encompass both labor demand and supply considerations with respect to mortality risk. Hence, a high death risk gradient in wages could reflect high employer aversion to the public image costs of employee deaths, as much as a high aversion of workers to their own death.

Our approach addresses the issues raised by Ashenfelter (2006). First, we fully allow for endogenous adjustments in the optimal allocations resulting from changes in death risk exposure when we compute the willingness to pay and the VSL. Second,

 $<sup>^{12}</sup>$ Indeed, mortality is treated exogenously in our baseline model. The more general setup with endogenous death risk exposure in Section 6.3 yields similar empirical results.

agency issues are absent as the agent bears the entire costs and benefits of changes in mortality. Third, whose preferences are at stake is not an issue as the latter are jointly estimated with the WTP and life valuations by resorting to a widely-used households' panel (PSID). Consequently, these values can safely be considered as representative of the general population. Fourth, labor demand considerations are absent as our partial equilibrium approach takes the return on investment as mortality-risk independent in characterizing the agent's optimal human capital allocations, i.e. only labor supply features are accounted for. More fundamentally, we neither rely on the wage/fatality nexus, nor on any other proxy and we make no assumption on the shape of the WTP function but rather derive its properties from the indirect utility function induced by the optimal allocation.

# 2 A Common Framework for Life Valuation

This section outlines an encompassing framework that will be relied upon to formally define and compare the willingness to pay, as well as the Human Capital, Statistical and Gunpoint Values of Life. Our main building block is a generic human capital problem for which the optimal policies and associated indirect utility function can be obtained in closed form. We combine these solutions with standard asset pricing and Hicksian variational analysis to characterize the three life valuations.

### 2.1 Generic Human Capital Problem

Consider an agent's human capital problem where the planning horizon is limited by a stochastic age at death  $T_m$  satisfying:

$$\lim_{h \to 0} \frac{1}{h} \Pr\left[T_m \in (t, t+h] \mid T_m > t\right] = \lambda_m,$$

such that the probability of death by age t is monotone increasing in  $\lambda_m$ :

$$\mathcal{P}(t) = \Pr(T_m \le t)$$

$$= 1 - e^{-\lambda_m t}.$$
(1)

In the subsequent analysis, we will focus on changes in death risk exposure  $\mathcal{P}$  resulting from changes in the Poisson death intensity  $\lambda_m$ .

Denote the agent's human capital H (e.g. skills or health) and associated increasing income function Y(H), as well as a financial wealth W, with corresponding distributional assumptions. For this program, the agent selects the money value of investment in his human capital I and other controls X (e.g. consumption, or asset allocation, ...) so as to maximize utility U:

$$V(W, H, \mathcal{P}) = \sup_{I, X} U, \text{ subject to:}$$
  

$$dH = dH(H, I),$$
  

$$dW = dW(W, Y(H), I, X).$$
(2)

We assume that the agent's preferences and constraints in (2) satisfy standard properties such that the indirect utility  $V = V(W, H, \mathcal{P})$  is monotone increasing and concave in W. We further assume preference for life over death:

$$V(W, H, \mathcal{P}) \ge V^m > -\infty, \quad \forall W, H, \mathcal{P},$$
(3)

where  $V^m = V(W, H, 1)$  denotes the finite utility at death.<sup>13</sup> Finally, the agent's problem is assumed to be sufficiently well-defined to guarantee the existence of decreasing and convex indifference curves in the wealth and life probability  $(1 - \mathcal{P})$  space (see Figure 1).

### 2.2 Human Capital Value of Life

The Human Capital Value of life is the market value of the net dividend flow associated with human capital and that is foregone upon death (e.g. Huggett and Kaplan, 2016, 2013). In our setting, this net dividend is the marketed income, minus the money value of investment expenses, where both are evaluated at the optimum to problem (2):

**Definition 1 (HK value of life)** The Human Capital Value of life  $v_{h,t} = v_h(W_t, H_t, \mathcal{P}_0)$ is the expected discounted present value over stochastic horizon  $T_m$  of labor revenue flows,

<sup>&</sup>lt;sup>13</sup>Standard examples of the latter include the seminal Yaari (1965); Hakansson (1969) paradigm ( $V^m \equiv 0$ ), or 'warm glow' effects of bequeathed wealth ( $V^m = V^m(W_{T_m})$ , e.g. Yogo (2016); French and Jones (2011); De Nardi et al. (2009)).

net of investment costs:

$$v_{h,t} = E_t \int_t^{T_m} m_{t,\tau} \left[ Y(H_\tau^*) - I_\tau^* \right] \mathrm{d}\tau,$$
(4)

where  $m_{t,\tau}$  is a stochastic discount factor induced by the assets' prices and  $(H^*, I^*)$  are evaluated along the optimal path solving (2).

As a canonical example, assume a constant interest rate r and that the net dividends are  $Y(H^*) - I^* = Y(0) + Y_n(H^*)$ , where  $Y_n(H^*)$  grows at constant rate  $g_n$  along the optimal path. The HK value in (4) then simplifies to:

$$v_h = \frac{Y(0)}{r + \lambda_m} + \frac{Y^n(H)}{r + \lambda_m - g_n}.$$
(5)

The human capital value of life in this special case is therefore decreasing in both the death risk  $\lambda_m$  and interest rate r and is increasing in both Y(0),  $Y^n(H)$ , as well as the growth rate  $g_n$ .

### 2.3 Willingness to pay

Next, consider a permanent exogenous change  $\Delta$  in the probability of death from base level  $\mathcal{P}_0$  in (1). We rely on the indirect utility (2) to define the Hicksian Equivalent Variation as follows:

**Definition 2 (WTP)** The willingness to pay  $v = v(W, H, \mathcal{P}_0, \Delta)$  to avoid a permanent change  $\Delta \in [-\mathcal{P}_0, 1-\mathcal{P}_0]$  in base death risk exposure  $\mathcal{P}_0$  is implicitly given as the solution to:

$$V(W - v, H, \mathcal{P}_0) = V(W, H, \mathcal{P}_0 + \Delta), \qquad (6)$$

where  $V(W, H, \mathcal{P})$  solves (2) and satisfies (3).

For unfavorable changes  $\Delta > 0$ , equation (6) indicates indifference between paying the equivalent variation v > 0 to remain at base risk and not paying, but facing higher death

risk. For favorable changes  $\Delta < 0$ , the agent is indifferent between receiving compensation -v > 0 and foregoing lower death risk exposure.<sup>14</sup>

Observe that the properties of the willingness to pay with respect to the increment in death risk  $v(\Delta)$  follow directly from those of the indirect utility  $V(W, H, \mathcal{P})$  in (2). In particular, consider the case where preference for life in (3) induces a decreasing and convex indirect utility with respect to the death probability  $\mathcal{P}$ . We can substitute  $v(W, H, \mathcal{P}_0, \Delta)$  in (6), take derivatives and re-arrange to obtain:

$$\frac{\partial v}{\partial \Delta} = \frac{-V_{\mathcal{P}}}{V_W} \ge 0,\tag{7a}$$

$$\frac{\partial^2 v}{\partial \Delta^2} = \frac{V_{\mathcal{P}\mathcal{P}} - V_{WW} \left( \frac{\partial v}{\partial \Delta} \right)^2}{-V_W} \le 0.$$
(7b)

Monotonicity  $V_W \ge 0$  and preference for life over death  $V_{\mathcal{P}} \le 0$  therefore induce a willingness to pay v that is increasing in  $\Delta$ , whereas the diminishing marginal utility of wealth  $V_{WW} \le 0$  and of survival probability  $V_{\mathcal{PP}} \ge 0$  are sufficient to induce a concave WTP function in mortality risk exposure.

#### 2.4 Value of Statistical Life

The VSL is a measure of the marginal rate of substitution between the probability of life and wealth, evaluated at base risk (e.g. Aldy and Smyth, 2014; Andersson and Treich, 2011; Bellavance et al., 2009; Murphy and Topel, 2006). In the context of our framework and relying on the WTP property (7a), the VSL can be defined as follows:

**Definition 3 (VSL)** The Value of a Statistical Life  $v_s = v_s(W, H, \mathcal{P}_0)$  is the negative of the marginal rate of substitution between the probability of death and wealth computed from the indirect utility  $V(W, H, \mathcal{P})$  evaluated at base risk  $\mathcal{P}_0$ :

$$v_s = \left. \frac{-V_{\mathcal{P}}(W, H, \mathcal{P})}{V_W(W, H, \mathcal{P})} \right|_{\mathcal{P}=\mathcal{P}_0}$$
(8a)

<sup>14</sup>An alternative formulation relies instead on the Hicksian willingness to accept compensation (WTA) to face  $\Delta$ , implicitly defined as the solution to:

$$V(W + v^{a}, H, \mathcal{P}_{0} + \Delta) = V(W, H, \mathcal{P}_{0}).$$

This WTA perspective however is not suitable in a money-or-life setup in the absence of bequests. Indeed, whereas paying out the WTP in a highwaymen threat is rational, accepting compensation against certain death when terminal wealth in not bequeathed and life is preferred is not. Since we abstract from bequests in our benchmark model in Section 3, we therefore adopt the WTP perspective in (6).

where  $V(W, H, \mathcal{P})$  solves (2) and satisfies (3).

Figure 1 illustrates the indifference curve (in blue) in the wealth and life probability space. The VSL in (8a) is the slope of the dashed red tangent evaluated at base death risk  $\mathcal{P}_0$ and is equivalent to the total wealth spent to save one life corresponding to the distance [a,d] (e.g. Andersson and Treich, 2011, Fig. 17.1, p. 398). Equivalently, the marginal rate of substitution between life and wealth in (8a) is implicitly associated to the relative price of a (non-marketable) life.

Moreover, we can rely on the WTP property (7a) to rewrite the VSL in (8a) as a marginal willingness to pay:

$$v_{s}(W, H, \mathcal{P}) = \frac{\partial v(W, H, \mathcal{P}_{0}, \Delta)}{\partial \Delta} \Big|_{\mathcal{P}=\mathcal{P}_{0}},$$

$$= \lim_{\Delta \to 0} \frac{v(W, H, \mathcal{P}_{0}, \Delta)}{\Delta}.$$
(8b)

Contrasting the theoretical definition of the VSL as a MWTP in (8b) with its empirical counterpart reveals the links between the two measures. Indeed the empirical VSL commonly relied upon in the literature can be expressed as:

$$v_s^e(W, H, \mathcal{P}_0, \Delta) = \frac{v(W, H, \mathcal{P}_0, \Delta)}{\Delta},\tag{9}$$

for small increment  $\Delta = 1/n$ , where *n* is the size of the population affected by the change (e.g. see footnote 3). The theoretical measure of the VSL in (8b) is the limiting value of its empirical counterpart in (9) when the change  $\Delta$  tends to zero. The importance of the bias between the empirical and theoretical VSL's  $(v_s^e - v_s)$  will consequently depend on the curvature of the willingness to pay v, as well as on the size and sign of the change  $\Delta$ , an issue to which we will return shortly.

#### 2.5 Gunpoint Value of Life

We next introduce the Gunpoint Value (GPV) as a third approach to the valuation of life. To do so, we combine preference for life (3) with the Hicksian Equivalent Variation in (6) to define the GPV as follows: **Definition 4 (GPV)** The Gunpoint Value  $v_g = v_g(W, H, \mathcal{P}_0)$  is the WTP to avoid certain, instantaneous death and is implicitly given as the solution to:

$$V(W - v_g, H, \mathcal{P}_0) = V^m \tag{10}$$

where  $V(W, H, \mathcal{P})$  solves (2) and satisfies (3) and where  $V^m$  is the utility at death.

The Gunpoint Value  $v_g(W, H, \mathcal{P}_0)$  in (10) is implicitly defined as the payment that leaves the agent indifferent between paying  $v_g$  and remaining at base death risk  $\mathcal{P}_0$  and not paying and facing instantaneous and certain death and attain utility  $V^m$ . The willingness to pay  $v_g$  can thus be interpreted as the maximal amount paid in order to survive an *ex-ante* unforecastable and *ex-post* credible highwaymen threat.

Compared to the HK and VSL alternatives, the Gunpoint Value presents several advantages. First, unlike the HK, the Gunpoint Value does not uniquely ascribe the economic worth of an agent to the capitalized net labor income that agent generates. Second, unlike the VSL, the GPV does not extrapolate measurable responses to small probabilistic changes in the likelihood of death, but instead explicitly values a person's life as an entity and does so without external assumptions regarding integrability from marginal to total value of life. Finally, instead of calculating an external valuation of someone's life, the GPV circumvents ethical discomforts by letting someone compute his own intrinsic value through his willingness to pay to save *himself*.

#### 2.6 Clarifying the links between the WTP, VSL and the GPV

Figure 2 illustrates the central role of the willingness to pay in linking the theoretical and empirical Statistical, as well as the Gunpoint Values of life. From properties (7), the WTP  $v = v(W, H, \mathcal{P}_0, \Delta)$  (solid blue line) is an increasing, concave function of the change in death risk  $\Delta \in [-\mathcal{P}_0, 1 - \mathcal{P}_0]$  when the indirect utility  $V(W, H, \mathcal{P})$  is decreasing and convex in  $\mathcal{P}$ . The theoretical VSL  $v_s$  in (8b) is the marginal willingness to pay, i.e. the slope of the dashed red tangent evaluated at base death risk ( $\Delta = 0$ ). It is equivalent to the linear projection corresponding to the total wealth spent to save one person (i.e. when  $\mathcal{P}_0 + \Delta = 1.0$ ) and is equal to the distance [a,f]. The empirical Value of a Statistical Life  $v_s^e$  in (9) is computed for a small change  $\Delta^e > 0$  and is the slope of the dashed-dotted green line; equivalently, it is the linear projection represented by the distance [b,e]. The empirical VSL measure  $v_s^e$  will thus understate its theoretical counterpart  $v_s$  when  $\Delta^e \gg 0$ and when the WTP is concave. Moreover, as will become clear shortly, the Gunpoint value corresponds to an admissible upper bound on the WTP, i.e. the limiting WTP when death is certain as represented by the distance [c,d] in Figure 2. A concave WTP entails that a linear extrapolation under either the theoretical, or the empirical VSL will thus overstate the Gunpoint value attributed to one's own life.

# 3 A Parametrized Human Capital Model

We now parametrize the generic human capital model in Section 2.1 in order to compute the willingness to pay and theoretical life values defined in Sections 2.2–2.5.

#### **3.1** Economic environment

Consider a stochastic, depreciable human capital  $H_t$  whose law of motion is given by:

$$dH_t = \left[I_t^{\alpha} H_t^{1-\alpha} - \delta H_t\right] dt - \phi H_t dQ_{st}.$$
(11)

The Cobb-Douglas parameter  $\alpha \in (0, 1)$  captures diminishing returns to investment. Deterministic depreciation occurs at rate  $\delta \in (0, 1)$ , whereas  $dQ_{st}$  is a Poisson depreciation shock with constant intensity  $\lambda_s$ , whose occurrence further depreciates the capital stock by a factor  $\phi \in (0, 1)$ .

The law of motion (11) applies to alternative interpretations of human capital. If  $H_t$  is associated with skills (e.g. Ben-Porath, 1967; Heckman, 1976), then investment  $I_t$  comprises education and training choices made by the agent whereas  $dQ_{st}$  can be interpreted as stochastic unemployment, or technological obsolescence shocks that depreciate the human capital stock. If  $H_t$  is instead associated with health (e.g. Grossman, 1972; Ehrlich and Chuma, 1990), then investment takes place through medical expenses or healthy lifestyle decisions whereas the stochastic depreciation occurs through morbidity shocks.

The agent's income Y(H) is given by:

$$Y_t = y + \beta H_t, \tag{12}$$

and comprises an exogenous base income y, whereas the expression  $\beta H$  reflects a positive income gradient for agents with higher human capital. Individuals can trade in two risky assets to smooth out shocks to consumption: stocks and insurance against human capital depreciation. Financial wealth  $W_t$  evolves according to the dynamic budget constraint:

$$dW_t = [rW_t + Y_t - c_t - I_t] dt + \pi_t \sigma_S [dZ_t + \theta dt] + x_t [dQ_{st} - \lambda_s dt], \qquad (13)$$

where r is the interest rate and  $\theta = \sigma_S^{-1}(\mu - r)$  is the market price of financial risk. In addition to investment  $I_t$ , the control variables include consumption  $c_t$ , the risky portfolio  $\pi_t$  and the units  $x_t$  of actuarially-fair depreciation insurance. The latter pays one unit of the numeraire per unit of contract purchased, upon occurrence of the depreciation shock and can be interpreted as unemployment insurance (if  $H_t$  is associated with skills) or as medical, or disability insurance (if  $H_t$  is associated with health). Note that the agent's investment opportunity set captured by the budget constraint (13) induces the following expression for the stochastic discount factor:

$$m_t = \exp\left(-rt - \theta Z_t - 0.5 \,\theta^2 t\right), \quad \text{with } m_{t,\tau} = m_\tau / m_t,$$

that will be used to compute the net present values, notably the HK value in (4).

Finally, the indirect utility of an alive agent is defined as:

$$V(W_t, H_t) = \sup_{(c,\pi,x,I)} U_t, \tag{14a}$$

where preferences are:

$$U_t = E_t \int_t^{T_m} \left( f(c_\tau, U_\tau) - \frac{\gamma |\sigma_\tau(U)|^2}{2U_\tau} \right) \mathrm{d}\tau, \tag{14b}$$

where the age at death  $T_m$  is the first occurrence of a Poisson process with constant intensity  $\lambda_m$  in (1) and where the Kreps-Porteus aggregator is:

$$f(c_t, U_t) = \frac{\rho U_t}{1 - 1/\varepsilon} \left( \left( \frac{c_t - a}{U_t} \right)^{1 - \frac{1}{\varepsilon}} - 1 \right).$$
(14c)

The utility function in (14) corresponds to the stochastic differential utility proposed by Duffie and Epstein (1992), i.e. the continuous-time analog to the discrete-time Epstein and Zin (1989, 1991) preferences. It is characterized by subjective discount rate  $\rho > 0$ , minimal subsistence consumption a > 0 and disentangles the elasticity of inter-temporal substitution (EIS)  $\varepsilon \ge 0$ , from the agent's constant relative risk aversion with respect to financial risk  $\gamma \ge 0$ . As explained in Hugonnier et al. (2013) and confirmed in Theorem 1 below, the homogeneity properties of non-expected utility guarantee that minimal consumption requirement  $c_t \ge a$  is associated with positive continuation utility and therefore preference of life over death  $V_t \ge V^m \equiv 0$ .

**Remark 1** The model assumes that the sole motivation for investing in  $H_t$  relates to its positive effects on marketed income in (12).<sup>15</sup> However, the valuation of human capital can also be made with respect to its non-marketed services. Indeed, the model can be adapted for non-workers by first defining  $\tilde{c}_t = c_t - \beta H_t$ , then eliminating  $\beta H_t$  in the income equation (12) and finally replacing for  $c_t = \tilde{c}_t + \beta H_t$  in the budget constraint (13) and preference equations (14). The agent then selects  $\tilde{c}_t$  and the other controls taking into account the beneficial utilitarian flow of human capital. As shown in Hugonnier et al. (2013, Remark 3), the theoretical results are unaffected under this alternative interpretation.

### 3.2 Optimal rules

The agent's dynamic problem (14), subject to (11) and (13) can either be solved directly through the Hamilton-Jacobi-Bellman (HJB) or in two separate stages, following the method outlined in Hugonnier et al. (2013). The two-step approach involves:

1. An *hypothetical* infinitely-lived agent first solves the optimal investment by maximizing the discounted value of the *H*-dependent part of net income:

$$P(H_t) = \sup_{I \ge 0} E_t \int_t^\infty m_{t,\tau} \left(\beta H_\tau - I_\tau\right) \mathrm{d}\tau.$$
(15)

 $<sup>^{15}{\</sup>rm Section}$  6.3 allows for additional beneficial effects of human capital on morbidity and mortality risk exposure.

The human wealth P(H) is combined with financial wealth and the NPV of the base income stream, net of minimal consumption to recover net total wealth as:

$$N(W_t, H_t) = W_t + \frac{y-a}{r} + P(H_t),$$
  
=  $W_t + E_t \int_t^\infty m_{t,\tau} \left[ Y(H_\tau^*) - I_\tau^* - a \right] d\tau.$  (16)

The characterization of this hypothetical problem entails that both the optimal investment, the human and net total wealth are mortality- and (with the exception of minimal consumption a) preferences-independent.

2. The finitely-lived agent then selects the remaining policies  $\bar{c}_t = c_t - a$ ,  $\pi_t$  as well as  $\bar{x}_t = x_t - \phi P(H_t)$  by maximizing utility (14), subject to the law of motion for net total wealth:

$$dN_t = (rN_t - \bar{c}_t)dt + \pi_t \sigma_S (dZ_t + \theta dt) + \bar{x}_t [dQ_{st} - \lambda_s dt].$$

The remaining optimal consumption, portfolio and insurance policies, as well as indirect utility function are calculated as functions of  $P(H_t)$  and  $N(W_t, H_t)$  and encompass explicit adjustments for finite lives where appropriate.

It is straightforward to show that both the HJB and 2-step methods are equivalent and yield the following optimal policies.

**Theorem 1** Assume that the following regularity conditions hold:

$$A(\lambda_m) = \varepsilon \rho + (1 - \varepsilon) \left( r - \lambda_m + 0.5 \ \theta^2 / \gamma \right) > \max \left( 0, r - \lambda_m + \theta^2 / \gamma \right), \tag{17a}$$

$$(r+\delta+\phi\lambda_s)^{\frac{1}{\alpha}}>\beta.$$
 (17b)

Then,

1. the human wealth and net total wealth are given as:

$$P(H_t) = BH_t \ge 0,\tag{18}$$

$$N(W_t, H_t) = W_t + \frac{y-a}{r} + P(H_t) \ge 0,$$
(19)

where B > 0 solves g(B) = 0, s.t. g'(B) < 0 in:

$$g(B) = \beta - (r + \delta + \phi \lambda_s)B - (1 - 1/\alpha)(\alpha B)^{\frac{1}{1 - \alpha}}$$

$$\tag{20}$$

and

2. the indirect utility for the agent's problem is:

$$V_t = \Theta(\lambda_m) N(W_t, H_t) \ge 0, \tag{21a}$$

$$\Theta(\lambda_m) = \tilde{\rho} A(\lambda_m)^{\frac{1}{1-\varepsilon}} \ge 0, \quad \tilde{\rho} = \rho^{\frac{-\varepsilon}{1-\varepsilon}}$$
(21b)

and generates the optimal rules:

$$c_{t} = a + A(\lambda_{m})N(W_{t}, H_{t}) \geq 0,$$
  

$$\pi_{t} = (\theta/(\gamma\sigma_{S}))N(W_{t}, H_{t}),$$
  

$$x_{t} = \phi P(H_{t}) \geq 0,$$
  

$$I_{t} = \left(\alpha^{\frac{1}{1-\alpha}}B^{\frac{\alpha}{1-\alpha}}\right)P(H_{t}) \geq 0,$$
  
(22)

where any dependence on death intensity  $\lambda_m$  is explicitly stated.

The two regularity conditions (17) are required to ensure positive marginal propensity to consume A > 0, for minimal consumption requirements  $c_t > a$  and for appropriate transversality restriction for both the value function and the shadow value of human capital. The price B in (18) can be interpreted as a Tobin's-Q associated with human capital. It is implicitly defined in (20) as an increasing function of the income gradient  $\beta$ and is declining in the rate of interest r and the expected depreciation  $\delta + \phi \lambda_s$ .

Three features of the optimal rules are particularly relevant for life valuation. First, the two-step solution method ensures that both human wealth (18), as well as the net total wealth (19) are independent of the death intensity  $\lambda_m$ . Second and related, the exposure to exogenous death risk  $\lambda_m$  affects welfare via  $\Theta(\lambda_m)$  in (21b), through its impact on the marginal propensity to consume (MPC)  $A(\lambda_m)$  exclusively. Equation (17a) establishes that this MPC impact crucially depends on the elasticity of inter-temporal substitution  $\varepsilon$ . An increase in death risk  $\lambda_m$  induces heavier discounting of future utility flows, leading to two opposite outcomes on the marginal propensity to consume. On the one hand, more discounting of future consumption requires shifting current towards future consumption to maintain utility (i.e. by lowering the MPC). This effect is dominant at low elasticity of inter-temporal substitution  $\varepsilon \in (0, 1)$  and the MPC in (17a) is monotone decreasing. On the other hand, heavier discounting makes future consumption less desirable and shifts future towards current consumption (i.e. by increasing the MPC). This *Live Fast and Die Young* effect is dominant at high elasticity of inter-temporal substitution  $\varepsilon > 1$ .

Third, the welfare in (21) is monotone increasing and linear in both wealth and human capital stock and is monotone decreasing and convex in death risk exposure at all EIS levels since:

$$\Theta'(\lambda_m) = -\tilde{\rho}A(\lambda_m)^{\frac{\varepsilon}{1-\varepsilon}} \le 0, \tag{23a}$$

$$\Theta''(\lambda_m) = \tilde{\rho}\varepsilon A(\lambda_m)^{\frac{2\varepsilon-1}{1-\varepsilon}} \ge 0.$$
(23b)

Hence, whereas the sign of the effects of death risk  $\lambda_m$  on the MPC (17a) depends on the EIS, preference for life implies that higher mortality exposure always reduces the marginal value of net total wealth (21b) and therefore lowers welfare in (21a). Importantly, as shown in (7), a decreasing and convex effect of death risk on welfare entails that the willingness to pay is increasing and concave with respect to changes in the latter.

# 4 Willingness to Pay and Values of Life

We next calculate the model-implied life valuations of Section 2 relying on the solution for the parametrized human capital model of Section 3. We will assume throughout that the optimal rules outlined in Theorem 1 are being followed by the agents and will abstract from time subscripts whenever possible to alleviate notation.

### 4.1 Human Capital Value of Life

The HK value of life outlined in Definition 1 is computed as follows.

**Proposition 1 (HK value)** The Human Capital Value of life solving (4) is:

$$v_h(H,\lambda_m) = C_0 \frac{y}{r} + C_1 P(H)$$

$$\tag{24}$$

where the constants  $(C_0, C_1) \in [0, 1]^2$  are defined by:

$$C_0 = \frac{r}{r + \lambda_m},\tag{25a}$$

$$C_1 = \frac{r - (\alpha B)^{\frac{\alpha}{1-\alpha}}}{r + \lambda_m - (\alpha B)^{\frac{\alpha}{1-\alpha}}},$$
(25b)

and where human wealth P(H) is given in (18).

Combining Definition (4) and the income equation (12) establishes that the HK value is the net present value of the net income flow  $y + \beta H - I(H)$ . Unlike step-1 in the solution method, this NPV is computed over a finite horizon and must be corrected for mortality exposure. The first term in (24) is the standard NPV of base income y = Y(0), calculated over an infinite horizon and corrected in (25a) for the exposure to death risk  $\lambda_m$  – see equation (5). The second expression is the net present value P(H) of the  $\beta H - I(H)$ term, also corrected for finite life horizon in (25b). Whereas a higher H unambiguously raises  $v_h$ , an increase in the Tobin's-Q, B, has two conflicting effects on the HK value. On the one hand, a higher shadow value P(H) = BH entails a larger  $v_h$ . On the other hand, a higher B raises the human capital foregone upon death and the finite life correction  $C_1$ decreases, thereby lowering  $v_h$ .

### 4.2 Willingness to pay to avoid a finite increase in death risk

We can next substitute the indirect utility  $V(W, H, \lambda_m)$  given by (21a) in Definition 2 and solve for the willingness to pay to avoid a change  $\Delta$  in death intensity. For that purpose, we must consider only the admissible changes for which the indirect utility remains well defined when evaluated at the modified death intensity. In particular, define the k-vector of all the model's base parameters  $\boldsymbol{\theta} = (\lambda_m; \alpha, \delta, ...)$  and let  $\boldsymbol{\theta}^* = (\lambda_m^*; ...)$  be the corresponding vector following the change to  $\lambda_m^* = \lambda_m + \Delta$ . The admissible sets are those where the parameters satisfy the transversality conditions:

$$\mathcal{A} = \left\{ \boldsymbol{\theta} \in \mathbb{R}^k_+ : \text{conditions (17) are satisfied} \right\},$$
$$\mathcal{A}_m = \left\{ \Delta \ge -\lambda_m : \boldsymbol{\theta}^* \in \mathcal{A} \right\}.$$

We henceforth restrict our analysis to the  $\mathcal{A}_m$  subset and solve the WTP as follows.

**Proposition 2 (willingness to pay)** The willingness to pay solving (6) to avoid an admissible change  $\Delta \in \mathcal{A}_m$  from  $\lambda_m$  to  $\lambda_m^* = \lambda_m + \Delta$  is given by:

$$v(W, H, \lambda_m, \Delta) = \left[1 - \frac{\Theta(\lambda_m^*)}{\Theta(\lambda_m)}\right] N(W, H),$$
(26)

an increasing and concave function of  $\Delta$  that is bounded by:

$$\inf_{\Delta \in \mathcal{A}_m} v(W, H, \lambda_m, \Delta) = \left[1 - \frac{\Theta(0)}{\Theta(\lambda_m)}\right] N(W, H)$$
(27a)

$$\sup_{\Delta \in \mathcal{A}_m} v(W, H, \lambda_m, \Delta) = N(W, H).$$
(27b)

where net total wealth N(W, H) is given in (19) and the marginal value  $\Theta(\lambda_m)$  is given in (21b).

The WTP in (26) equals zero whenever the increment  $\Delta = 0$ , as well as under unit elasticity of inter-temporal substitution  $\varepsilon = 1$ . In this case, the marginal value of total wealth  $\Theta$  is independent from  $\lambda_m$ . For the other cases, it was shown earlier that  $\Theta(\lambda_m) \ge 0$ in (21b) is a decreasing and convex function. Consequently, the weights  $\Theta(\lambda_m^*)/\Theta(\lambda_m) \in$ [0, 1] for detrimental changes  $\Delta \ge 0$  and the willingness to pay is an increasing function of net total wealth N(W, H).

Furthermore, a decreasing  $V_{\mathcal{P}} \leq 0$  and convex  $V_{\mathcal{PP}} \geq 0$  indirect utility in equation (7) entails a monotone increasing and concave willingness to pay to avoid death. These properties of the indirect utility were verified in (23) and the implications for the WTP are again confirmed in (26). They are consistent with standard economic intuition of diminishing marginal valuation of exposure to death (e.g. Philipson et al., 2010; Córdoba and Ripoll, 2017).

Equation (27a) establishes that the admissible lower bound on the WTP is obtained by setting  $\Delta = -\lambda_m$ . From equations (17a) and (21b) this bound exists and is finite. Equation (27b) establishes that the willingness to pay is bounded above by net total wealth N(W, H). When the elasticity of inter-temporal substitution is larger than one, this upper bound corresponds to the asymptotic WTP. When the EIS is below one, the upper bound corresponds to a maximal admissible WTP satisfying the transversality constraint (17a) (see Appendix B.3).

### 4.3 Value of a Statistical Life

Using Definition 3 and welfare (21), we can calculate the theoretical expression for the VSL for the parametrized model as follows.

**Proposition 3 (Value of Statistical Life)** The Value of a Statistical Life is:

$$v_s(W, H, \lambda_m) = \frac{1}{A(\lambda_m)} N(W, H),$$
(28)

where the marginal propensity to consume  $A(\lambda_m)$  is given in (17a) and net total wealth N(W, H) is given in (19).

The Value of a Statistical life reflects the marginal rate of substitution between wealth and life. It is unconditionally decreasing in the MPC and increasing in net worth. Observe that since the MPC is typically low (e.g. see Carroll, 2001, for a review), the VSL is thus expected to be larger than net disposable resources N(W, H), an issue to which we will return shortly.

Remark 2 (empirical VSL as a collective WTP) We can assess the claim by the empirical VSL literature that the average willingness to pay over small  $\Delta$  in (9) measures a *collective*, rather than individual, willingness to pay to save a human life. Given a population of agents j = 1, 2, ..., n, as well as any set of social weights  $\eta \in \mathbb{R}^n_+$ , we can assume homogeneous parameters  $\theta_j = \theta, \forall j$  and exploit the linearity of the WTP function (26) in wealth and human capital in order to derive the (weighted) collective WTP as:

$$\sum_{j=1}^{n} \eta_j v_j(W_j, H_j, \lambda_m, \Delta) = \left[1 - \frac{\Theta(\lambda_m^*)}{\Theta(\lambda_m)}\right] \sum_{j=1}^{n} \eta_j N(W_j, H_j).$$
(29)

Two special cases of identical weights  $\eta$  in (29) are worth mentioning:

1. Proportional weights  $\eta_j = 1/n, \forall j$  yield:

$$\bar{v}(W, H, \lambda_m, \Delta) = \left[1 - \frac{\Theta(\lambda_m^*)}{\Theta(\lambda_m)}\right] N(\bar{W}, \bar{H}),$$
$$= v(\bar{W}, \bar{H}, \lambda_m, \Delta).$$

The collective WTP – corresponding to the mean willingness to pay  $\bar{v}$  – is the WTP (26) evaluated at the mean wealth and human capital  $(\bar{W}, \bar{H})$ .

2. Unit weights  $\eta_j = 1, \forall j$  yield:

$$\sum_{j=1}^{n} v_j(W_j, H_j, \lambda_m, \Delta) = \left[1 - \frac{\Theta(\lambda_m^*)}{\Theta(\lambda_m)}\right] nN(\bar{W}, \bar{H}),$$
$$= nv(\bar{W}, \bar{H}, \lambda_m, \Delta).$$

Evaluating the latter at  $\Delta = n^{-1}$  yields the empirical VSL measure commonly used in the literature:

$$\sum_{j=1}^{n} v_j(W_j, H_j, \lambda_m, \Delta) = \frac{v(\bar{W}, \bar{H}, \lambda_m, \Delta)}{\Delta} = v_s^e(\bar{W}, \bar{H}, \lambda_m, \Delta).$$
(30)

Hence, the empirical VSL  $v_s^e$  in (9), or (30) is indeed a collective WTP, under homogeneity and unit social weights assumptions and corresponds to an infra-marginal WTP, i.e. a slope between two points on the willingness to pay, where the latter is evaluated at mean wealth and human capital  $(\bar{W}, \bar{H})$ . As discussed earlier, a concave WTP implies that  $v_s^e \leq v_s$  for  $\Delta \geq 0$ , i.e. the empirical measure under-estimates the theoretical VSL corresponding to the MWTP (see Figure 2).

Remark 3 (discrete changes per period) The theoretical calculations of the VSL in equation (28) are valid for permanent changes in the death intensity. In the spirit of the empirical VSL literature, the value of a statistical life can also be computed as the willingness to pay to avoid an exogenous increase  $\Delta$  in the probability of death over a given time interval (e.g. a change  $\Delta = 0.1\%$  per one year period), divided by  $\Delta$ . This calculation can also be obtained in closed-form and involves two steps. First, the new value of the endowed intensity  $\lambda_m^*(\Delta, T)$  is computed, corresponding to a change in death risk  $\Delta$  occurring over a duration of T:

**Lemma 1** A higher likelihood of death of  $\Delta$  per time interval of  $s \in [0,T]$  corresponds to a permanent increase in the endowed intensity to  $\lambda_m^*(\Delta,T) > \lambda_m$  given by:

$$\lambda_m^*(\Delta, T) = \frac{-1}{T} \log \left[ e^{-\lambda_m T} - \Delta \right].$$
(31)

Second, we can substitute  $\Theta(\lambda_m^*(\Delta, T))$  in the WTP (26) and divide by  $\Delta$  to obtain the corresponding empirical Value of a Statistical Life.

#### 4.4 Gunpoint Value of Life

Combining Definition 4 and (21) reveals the following result for the GPV.

**Proposition 4 (Gunpoint value of life)** The willingness to pay to avoid instantaneous and certain death solving (10) is given by:

$$v_q(W,H) = N(W,H),\tag{32}$$

where N(W, H) is the net total wealth in (19).

In the absence of a bequest motive, the agent who is forced to evaluate life at gunpoint would be willing to pay the *hypothetical* (i.e. step-1) value of pledgeable resources. The discussion of net total wealth in (16) establishes that this amount corresponds to his entire financial wealth W, plus the capitalized value of his net income along the optimal path  $Y(H^*) - I^*$ . However, the previous discussion emphasized that the minimal consumption level a is required at all periods for subsistence. Its cost therefore cannot be pledged in a highwaymen threat and must be subtracted from the Gunpoint value.

Interestingly, since net total wealth is independent of risk aversion and elasticity of inter-temporal substitution, as well as of the death risk exposure, so is the GPV. The reason stems from the way the GPV is characterized in Definition 4, i.e. as the unitary value of a life, rather than by integrating marginal changes in death risk exposure. The agent therefore pays  $v_g$  to avoid receiving the utility  $V^m$  that is associated with certain and immediate death. Because the utility at death is a finite primitive and is normalized at zero, the Gunpoint Value is always computable for all EIS levels. For the same reason, the Gunpoint Value of life  $v_g$  in (32) is also independent from the agent's preferences  $(\rho, \varepsilon, \gamma)$  and from the death intensity  $(\lambda_m)$ . Because the outcome of death is certain when life is evaluated at gunpoint, the attitudes towards time and risk, as well as the level of exposure to death risk become irrelevant. Since death at gunpoint is instantaneous, attitudes towards inter-temporal substitution are irrelevant as well. It can also be shown (Hugonnier et al., 2013, Prop. 2) that net total wealth N(W, H)is equal to the expected discounted present value of excess consumption  $\bar{c}_t = c_t - a$  along the optimal path:

$$E_t \int_t^\infty m_{t,\tau} \bar{c}_\tau \mathrm{d}\tau = N(W_t, H_t).$$

In order to survive, the agent is thus willing to pledge the net present value of his optimal consumption stream (net of unpledgeable minimal subsistence), at which point he becomes indifferent between living and dying. This result can be traced to the homogeneity property of the Duffie and Epstein (1992) preferences under which the foregone utility is measured in the same units as the foregone excess consumption.

We previously explained that the first step to solve the optimal rules in Theorem 1 relied on an hypothetical agent's infinite-horizon problem to recover human wealth P(H) in (15), from which net total wealth N(W, H) is obtained in (16). The HK value (4) and (24) corrects this hypothetical human wealth for exposure to mortality risk. Consequently, the differences between the Gunpoint and HK values can be written as:

$$v_g(W_t, H_t) - v_h(H, \lambda_m) = W_t - \frac{a}{r} + (1 - C_0)\frac{y}{r} + (1 - C_1)P(H_t)$$

The first two terms reflect the financial wealth and (capitalized) minimal consumption that affect net total wealth and therefore optimal consumption and welfare, but have no effects on optimal investment and therefore on the optimal path for net income  $Y(H^*)-I^*$ . The third and last terms show the mortality risk adjustments  $(C_0, C_1) \in [0, 1]^2$  on the net cash flow that are present in the HK value but not in the GPV. Unless minimal consumption requirements a/r are very large, the Gunpoint Value is therefore expected to be larger than the Human Capital Value.

The links between the willingness to pay in (26) and the GPV in (32) are intuitive and follow directly from the properties of the WTP. Indeed, the Gunpoint Value corresponds to the admissible upper bound (27b) on the willingness to pay to avoid a change in death risk exposure:

$$v_g(W, H) = \sup_{\Delta \in \mathcal{A}_m} v(W, H, \lambda_m, \Delta).$$

This upper bound exists and is finite by admissibility, i.e. compliance with transversality restrictions. A concave willingness to pay thus implies that the VSL will necessarily over-value the GPV (see Figure 2). Indeed, comparing (28) and (32) establishes that:

$$v_q(W,H) = A(\lambda_m)v_s(W,H,\lambda_m).$$
(33)

Estimates of the marginal propensity to consume  $A(\lambda_m)$  are typically low, ranging from 2-9% for housing wealth and 6% for financial wealth (e.g. Carroll et al., 2011, p. 58). Consequently, the predicted gap between the GPV and VSL is positive and large.

Finally, our closed-form results also have implications for the optimal long-run allocation between safety- and consumption-enhancing innovations. Indeed, contrasting excess consumption  $\bar{c}_t = c_t - a$  with the Statistical and Gunpoint Values of life reveals that the growth rates are linked as follows:

$$g(\bar{c}_t) = g(N_t) = (W_t/N_t) g(W_t) + (H_t/N_t) g(H_t),$$
  
=  $g(v_{st}) = g(v_{gt}).$ 

Along the optimal path, consumption above subsistence  $\bar{c}_t$  grows at the same rate as the Statistical and Gunpoint Values of life, i.e. at the rate of growth of net total wealth. This could warrant allocating equal resources to life-saving and consumption-enhancing innovations.<sup>16</sup>

**Remark 4 (aging)** Our closed-form expressions for the willingness to pay and the three life valuations have thus far abstracted from aging processes. The latter can be incorporated for a wide pattern of age-dependencies, although at some non-negligible computation cost. In particular, Hugonnier et al. (2013, Appendix B) show that any admissible time variation in  $\lambda_{mt}$ ,  $\lambda_{st}$ ,  $\phi_t$ ,  $\delta_t$ , or  $\beta_t$  results in age-dependent MPC and

<sup>&</sup>lt;sup>16</sup>In particular, Jones (2016, p. 567) writes that:

<sup>&</sup>quot;When the value of life rises faster than consumption, economic growth leads to a disproportionate concern for safety. This concern may be so strong that it is desirable that consumption growth be restrained.  $[\ldots]$  It would clearly be desirable to have precise estimates of the value of life and on how this has changed over time; in particular, does it indeed rises faster than consumption?"

Tobin's-Q that solve the system of ordinary differential equations (ODE):

$$\dot{A}_t = A_t^2 - \left(\varepsilon\rho + (1-\varepsilon)\left(r - \lambda_{mt} + \theta^2/(2\gamma)\right)\right)A_t,$$
  
$$\dot{B}_t = (r + \delta_t + \phi_t \lambda_{st})B_t + (1 - 1/\alpha)(\alpha B_t)^{\frac{1}{1-\alpha}} - \beta_t,$$

subject to appropriate boundary conditions. Allowing for aging and solving for the ODE's  $A_t, B_t$  implies that the solutions for  $C_{0t}, C_{1t}$ , the marginal value  $\Theta_t(\lambda_{mt})$ , as well as the human and total wealth  $P_t(H), N_t(W, H)$  are also age-dependent. All the previous results remain applicable with these time-varying expressions.

## 5 Structural estimation

To structurally estimate the willingness to pay and the life valuations, we follow a long tradition associating the agent's human capital to his health (e.g. see the Hicks' lecture by Becker, 2007, for a review). We estimate the technological, preferences and stochastic parameters for the model outlined in Section 3 by using the theoretical decisions to model their observed counterparts. Once the structural parameters have been estimated, they can be relied upon to compute the closed-form expressions for the life valuations in Section 4.

#### 5.1 Econometric model

For identification purposes, the econometric model assumes that agents follow the optimal rules to the parametrized model and that they differ with respect to their health and wealth statuses, whereas they share common preference, technological and distributional parameters  $\boldsymbol{\theta} \in \mathbb{R}^{k}_{+}$ .<sup>17</sup> In particular, we use the closed-form expressions in Theorem 1 to which we append the income equation (12). Specifically, denote by  $\mathbf{Y}_{j} = [c_{j}, \pi_{j}, x_{j}, I_{j}, Y_{j}]'$ the 5 × 1 vector of observed decisions and income for agent  $j = 1, 2, \ldots, n$ , let  $\mathbf{X}_{j} =$  $[1, W_{j}, H_{j}]'$  capture his current wealth and health statuses. Also let  $\mathbf{B}(\boldsymbol{\theta})$  denote the 5 × 3 matrix of closed-form expressions for the optimal rules implicit in equation (22), that are functions of the structural parameters  $\boldsymbol{\theta}$ . The econometric model relies on

<sup>&</sup>lt;sup>17</sup>Observe that this identifying hypothesis is consistent with the aggregation assumptions required to elicit the empirical VSL as a collective WTP (see Remark 2).

Maximum Likelihood to structurally estimates the latter in:

$$\mathbf{Y}_j = \mathbf{B}(\boldsymbol{\theta})\mathbf{X}_j + \mathbf{u}_j \tag{34}$$

where the  $\mathbf{u}_j$ 's are (potentially correlated) Gaussian error terms. In order to ensure theoretical consistency (i.e.  $\boldsymbol{\theta} \in \mathcal{A}$ ) and augment identification, we estimate the structural parameters in (34) imposing the regularity conditions (17). Finally, identification requires calibrating a subset of parameters denoted  $\boldsymbol{\theta}^c$  and estimating the remaining ones.

#### 5.2 Data

We use a sample of n = 8,378 individuals taken from the 2013 wave of the Institute for Social Research's Panel Study of Income Dynamics (PSID). The data construction is detailed in Appendix D. We proxy the health variables through the polytomous selfreported health statuses (Poor, Fair, Good, Very Good and Excellent) that are linearly converted to numeric values from 1 to 4. The financial wealth comprises risky and riskless assets. Using the method in Skinner (1987), we infer the unreported total consumption by extrapolating the food, transportation and utility expenses reported in the PSID. Finally, health spending and health insurance expenditures are taken to be the out-ofpocket spending, as well as premia paid by agents. All nominal values are scaled by  $10^{-6}$ for the estimation.

Tables 1, and 2 present descriptive statistics for the main variables of interest, per health status and per wealth quintiles. Table 2.a shows that financial wealth remains very low for the first three quintiles (see also Hubbard et al., 1994, 1995; Skinner, 2007, for similar evidence). Moreover no clear relation between health and wealth can be inferred. The level of consumption in panel b is increasing in financial wealth, consistent with expectations. However, the effects of health remain ambiguous, except for the least healthy who witness a significant drop in consumption.

In panel c, stock holdings are very low for all but the fourth and fifth quintiles, illustrating the well-known non-participation puzzle (e.g. Friend and Blume, 1975; Mankiw and Zeldes, 1991). Again, a clear positive wealth gradient is observed, whereas health effects are weakly positive. The health insurance expenses in panel d are modest relative to consumption. They are increasing in wealth and devoid of clear health gradients. Finally, health spending in panel e is of the same order of magnitude as insurance. It is strongly increasing in wealth and also sharply decreasing in health status.

### 6 Results

#### 6.1 Structural parameters

Table 3 reports the calibrated (with subscripts  $^{c}$ ) and estimated (standard errors in parentheses) model parameters. Overall, the latter are precisely estimated and are consistent with other estimates for this type of model (e.g. Hugonnier et al., 2013, 2017).

First, the health law of motion parameters in panel a are indicative of significant diminishing returns in adjusting health status ( $\alpha = 0.6843$ ). Although deterministic depreciation is relatively low ( $\delta = 1.25\%$ ), morbidity is consequential with additional depletion of  $\phi = 1.36\%$  and average waiting time between occurrence of  $\lambda_s^{-1} = 28.8$  years. Second, exposure to mortality risk is realistic ( $\lambda_m = 0.0283$ ), corresponding to a remaining expected lifetime of  $\lambda_m^{-1} = 35.3$  years, given mean respondent age of 45.26 years in Table 1.<sup>18</sup>

Third, the income parameters in panel c are indicative of a significant positive effect of health on labor income ( $\beta = 0.0092$ ), as well as an estimated value for base income that is close to poverty thresholds ( $y \times 10^6 = 12.2 \text{ K}$ \$).<sup>19</sup> The financial parameters ( $\mu, \sigma_S, r$ ) are calibrated from the observed moments of the S&P500 and 30-days T-Bills historical returns. Finally, the preference parameters in panel d indicate realistic aversion to financial risk ( $\gamma = 2.8953$ ). The minimal consumption level is somewhat larger than base income ( $a \times 10^6 = 14.0 \text{ K}$ \$). As for other cross-sectional estimates using survey data (Gruber, 2013; Hugonnier et al., 2017), the elasticity of inter-temporal substitution is larger than one ( $\varepsilon = 1.2416$ ) and is consistent with a *Live Fast and Die Young* effect whereby a higher risk of death increases the marginal propensity to consume.

 $<sup>^{18}</sup>$ The remaining life expectancy at age 45 in the US in 2013 was 36.1 years (all), 34.1 (males) and 37.9 (females) (Arias et al., 2017).

 $<sup>^{19}</sup>$  For example, the 2016 poverty threshold for single-agent households under age 65 was 12.5 K\$ (U.S. Census Bureau, 2017).

#### 6.2 Estimated valuations

Human Capital Value of Life Using the estimated parameters in Table 3, we can compute the HK value of life  $v_h(H)$  given in (24) and reported in Table 4.a. Consistent with predictions, the human capital values are independent from W and increasing in H, ranging from 250 K\$ (Poor health) to 527 K\$ (Excellent health), with a mean value of 421 K\$. These figures are realistic. For example, setting Y(0) = y, using (scaled) mean income 21,838\$ minus expenses of 721 \$ in Table 1 to compute  $Y_n(H)$ , a mortality exposure  $\lambda_m = 0.0283$  and a constant net income growth rate  $g_n = 1\%$  yields a canonical HK value in (5) equal to 475 K\$. Our structural estimates also compare advantageously with HK estimates in the literature and provide a first out-of-sample confirmation that the structural estimates are reasonable.<sup>20</sup>

Value of Statistical Life Table 4.b reports the Values of Statistical Life  $v_s(W, H, \lambda_m)$ in (28) by observed health and wealth statuses. First, the VSL mean value is 8.35 M\$, with valuations ranging between 2.17 M\$ and 15.01 M\$. These values are well within the ranges usually found in the empirical VSL literature.<sup>21</sup> The concordance of these estimates with previous findings provides additional out-of-sample evidence that our structural estimates are well grounded. Importantly, our common framework for life valuation confirms that the large VSL-HK gap is *not* an artefact of disjoint theoretical and empirical approaches used in the literature.

Second, the VSL is increasing in both wealth and especially health. Positive wealth gradients have been identified elsewhere (Bellavance et al., 2009; Andersson and Treich, 2011; Adler et al., 2014) whereby diminishing marginal value of wealth and higher financial values at stake both imply that richer agents are willing to pay more to improve survival probabilities. The literature has been more ambivalent with respect to the health effect (e.g. Andersson and Treich, 2011; Robinson and Hammitt, 2016; Murphy and Topel, 2006). On the one hand better health increases the value of life that is at

 $<sup>^{20}{\</sup>rm Huggett}$  and Kaplan (2016, benchmark case, Fig. 7.a, p. 38) find HK values starting at about 300 K\$ at age 20, peaking at less than 900 K\$ at age 45 and falling steadily towards zero afterwards.

<sup>&</sup>lt;sup>21</sup>A meta-analysis by Bellavance et al. (2009, Tab. 6, p. 452) finds mean values of 6.2 M\$ (2000 base year, corresponding to 8.6 M\$, 2016 value). Survey evidence by Doucouliagos et al. (2014) ranges between 6 M\$ and 10 M\$. Robinson and Hammitt (2016) report values ranging between 4.2 and 13.7 M\$. Finally, guidance values published by the U.S. Department of Transportation were 9.6 M\$ in 2016 (U.S. Department of Transportation, 2016), whereas the Environmental Protection Agency relies on central estimates of 7.4 M\$ (2006\$), corresponding to 8.8 M\$ in 2016 (U.S. Environmental Protection Agency, 2017).

stake, on the other hand, healthier agents face lower death risks and are willing to pay less to attain further improvements (or prevent deteriorations). Since our benchmark model abstracts from endogenous mortality (see the robustness discussion in Section 6.3 for generalization) and better health increases net total wealth N(W, H), our estimates unambiguously indicate that the former effect is dominant and that improved health raises the VSL.

**Gunpoint Value** Table 4.c reports the Gunpoint values  $v_g(W, H)$  in (32). The mean GPV is 447 K\$ and the estimates are increasing in both health and wealth and range between 116 K\$ and 804 K\$. The Gunpoint Value is thus of similar magnitude to the Human Capital Value of life and both are much lower than the VSL. Indeed, this finding was already foreseeable from equation (33) indicating that the VSL/GPV ratio is inversely proportional to the marginal propensity to consume. Since our estimates reveal that  $A(\lambda_m) = 5.36\%$  – a value again well in line with other estimates (Carroll et al., 2011) – we identify a VSL that is 18.66 times larger than the GPV.

#### 6.3 Robustness

In order to verify robustness of the results, we consider a more general model of human capital. Hugonnier et al. (2013) study a demand for health framework that is similar to our benchmark, with two key differences. First, the model allows for self-insurance against morbidity and mortality risks by introducing health-dependent intensities:

$$\lambda_s(H_{t-}) = \eta + \frac{\lambda_{s0} - \eta}{1 + \lambda_{s1} H_{t-}^{-\xi_s}},$$
$$\lambda_m(H_{t-}) = \lambda_{m0} + \lambda_{m1} H_{t-}^{-\xi_m},$$

where  $H_{t-} = \lim_{s\uparrow t} H_s$  is health prior to the morbidity shock realization. Hence, better health lowers exposure to sickness and death risks and our benchmark model of Section 3 is an exogenous restricted case that imposes  $\lambda_{s1}, \lambda_{m1} = 0$ . Second, preferences are modified to allow for source-dependent aversion against financial, morbidity and mortality risks. In particular, the preferences in (14b) are replaced by:

$$U_t = E_t \int_t^{T_m} \left( f(c_{\tau}, U_{\tau-}) - \frac{\gamma |\sigma_{\tau}(U)|^2}{2U_{\tau-}} - \sum_{k=m}^s F_k(U_{\tau-}, H_{\tau-}, \Delta_k U_{\tau}) \right) \mathrm{d}\tau,$$

with the Kreps-Porteus aggregator (14c) unchanged and with penalties for exposure against Poisson sickness and death risks:

$$F_k = U_{t-} \lambda_k(H_{t-}) \left[ \frac{\Delta_k U_t}{U_{t-}} + u(1;\gamma_k) - u \left( 1 + \frac{\Delta_k U_t}{U_{t-}};\gamma_k \right) \right], \quad \text{where}$$
  
$$\Delta_k U_t = E_{t-} [U_t - U_{t-} | \mathrm{d}Q_{kt} \neq 0], \quad \text{and} \quad u(x;\gamma_k) = \frac{x^{1-\gamma_k}}{1-\gamma_k}.$$

Our benchmark specification is thus a restricted case that imposes risk-neutral attitudes towards morbidity ( $\gamma_s = 0$ ) and mortality ( $\gamma_m = 0$ ) risks.

In a separate technical appendix (available upon request), we show that the approximate closed-form expressions for the WTP, HK, VSL and GPV valuations can be obtained. These expressions encompass explicit adjustments for the endogeneity of health risks exposure and source-dependent risk aversion, yet remain otherwise qualitatively similar. We structurally estimate the Hugonnier et al. (2013) model and compute the life values. These values remain in the same range as our benchmark estimates, with mean HK of 493 K\$, VSL of 8.14 M\$ and GPV of 460 K\$ and again confirm the strong concavity of the WTP. We conclude that our main findings are qualitatively and empirically robust to more general specifications.

# 7 Discussion: Accounting for the Large VSL

### 7.1 Disjoint theoretical and empirical frameworks?

Our empirical results yields three main messages. First, contrasting reduced-form estimates obtained from separate settings in the empirical VSL literature with fully structural ones from a common model and data set produces very similar estimates for the HK and VSL life values. Equivalently, segmented reduced-form approaches do not exhibit readily identifiable biases when contrasted with a fully-encompassing theoretical and empirical approach. A second and related message is that the large discrepancies between the two main life valuations are therefore not a result of separate theoretical and empirical frameworks; these differences persist when we structurally estimate the closed-form expressions for the VSL and HK from a common setup. Third, the Human Capital Value is much closer to a natural benchmark given by the Gunpoint Value than the VSL is. Explanations other than segmented theoretical and empirical frameworks must therefore be analyzed to understand why the VSL is more than 18 times larger than the other two life values.

#### 7.2 Collective WTP vs individual MWTP?

Much has been made about a fundamental characterization of the VSL as a *collective* willingness to pay to save unidentified lives. When contrasted with an *individual* marginal WTP to save oneself, one could argue that there are no reasons to expect that the two should be equal (e.g. Pratt and Zeckhauser, 1996). However, we helped dispel this ambiguity by formally showing that the collective WTP can be calculated in closed-form and that this expression indeed corresponds to the average WTP value favored by the empirical VSL under suitable aggregation assumptions (see Remark 2). We also showed that the  $v_s^e$  nonetheless remains an infra-marginal approximation to the theoretical VSL  $v_s$  that will *under-state* the individual marginal rate of substitution under diminishing MWTP when computed for  $\Delta > 0$  instead of  $\Delta \rightarrow 0$ . The HK-VLS gaps are therefore larger when relying on the true MRS measure rather than on its empirical proxy.

We can verify this claim by computing the collective WTP corresponding to the empirical VSL  $v_s^e$  given in (30). Setting  $\Delta = 1/n = 1/8,378$  and  $\lambda_{m0}^* = \lambda_m + \Delta$ , we recover an aggregate VSL of 8.34 M\$, which, as expected, is lower, but very close to the mean theoretical value of  $v_s(W, H, \lambda_m) = 8.3515$  M\$.<sup>22</sup> This result thus confirms that the theoretical and empirical values are close to one another, i.e. the individual MWTP is well approximated by the collective WTP corresponding to the empirical VSL when  $\Delta = 1/n$  is small (i.e. the sample size is large). Equivalently, we cannot rely on any alleged opposition between a collective willingness to pay and an individual marginal WTP to rationalize the large VSL values.

#### 7.3 Diminishing MWTP?

We also showed that both the empirical and theoretical VSL will overstate the GPV corresponding to the upper bound on the concave willingness to pay. To help visualize this gap, Figure 3 is the estimated counterpart to Figure 2 and plots the willingness to

<sup>&</sup>lt;sup>22</sup>We can also use Lemma 1 to fix an arbitrary duration T = 1 for change  $\Delta$  and compute  $\lambda_{m0}^*(1/n, T)$  in (31), as well as  $\Delta_T = \lambda_{m0}^* - \lambda_m$ . Substituting the latter in (30) recovers an almost identical empirical value of  $v_s^e = 8.3396$  M\$.

pay  $v(W, H, \lambda_m, \Delta)$  as a function of  $\Delta$  calculated from (26) at the estimated parameters and relying on the mean wealth and health status. First, the estimated WTP (solid blue line) displays a pronounced curvature, consistent with our theoretical results. Second, equation (8) identified the VSL  $v_s(W, H, \lambda_m)$  as the MWTP, i.e. the value of the slope of the (red dashed) tangent of  $v(W, H, \lambda_m, \Delta)$  evaluated at  $\Delta = 0$ . Third, equations (27b) and (32) established that the upper bound of the willingness to pay is the net total wealth N(W, H) and that this limiting value is also the Gunpoint value  $v_g(W, H)$  (dashed-dotted black line). Finally, the HK value (dotted magenta) is independent of  $\Delta$  and is close to the GPV.

The strongly diminishing MWTP in Figure 3 is informative as to why the VSL is much larger than the Human Capital and Gunpoint values. Indeed, the agent is willing to pay 37 K\$ to avoid an increase of  $\Delta = 0.0047$  which shortens his horizon from 35.3 to 30.3 years and would pay 406 K\$ to avoid  $\Delta = 0.17$  which lowers expected remaining lifetime from 35.3 to only 5 years. This last value is already close to the HK and GPV values of 421 K\$ and 447 K\$, both of which are much lower than the VSL of 8.35 M\$. Equivalently, the linear extrapolation of marginal values that is relied upon in the VSL calculation overstates the willingness to protect one's own life when the WTP is very concave in the death risk increment, as foreshadowed in our discussion of (28) and (33) showing that the VSL is much larger than the total pledgeable resources that are paid out under a Gunpoint threat.

#### 7.4 Back to basics?

To summarize, our results confirm that the important discrepancies between the Human Capital and Statistical Life Values are not a consequence of treating the two separately in theoretical and empirical implementations. Moreover, opposing aggregate WTP vs individual MWTP's neither alleviates, nor rationalizes the large gaps. Furthermore, the HK valuation is much closer to the natural benchmark given by the Gunpoint Value, i.e. the upper bound on the willingness to pay. All elements point to the strongly diminishing marginal willingness to pay to avoid increases in death risk exposure as the sole remaining explanation.

Seen from that perspective only reaffirms the appropriateness of Schelling (1968)'s introductory warning that the VSL is a local measure of substitution rates between wealth

and life that should *not* be interpreted as the value of a given human being. Indeed, the linear extrapolation from a local to a holistic measure of life value is problematic under diminishing marginal willingness to pay. This extrapolation, to paraphrase Schelling's wording, is *treacherous* and best left to methods that abstract from integrating marginal values and value the whole life instead. Wrongful death litigation, or curative vs terminal care decisions all involve personalized, non-divisible and non-marketed life values. The VSL is inappropriate for these purposes for which the HK and GPV are the better alternatives.

On the other hand, the VSL adequately gauges a collective willingness to pay to attain or prevent changes in death risk exposure. Relying on the VSL thus appears fully warranted to compute a collective value on small indiscriminate reductions on mortality for which society will ultimately end up paying the costs. Market- and individual-based holistic valuations such as the HK and GPV are inadequate for these instances.

## 8 Conclusion

Computing the money value of a human being has long generated a profound and continued interest, with early records dating back to the late XVII<sup>th</sup> century. The two most widely-used valuation frameworks have centered on the marginal rate of substitution between the probability of living and wealth (VSL) and on a person's human capital value that is destroyed upon death (HK). Despite pricing a common element, the two life valuations yield strikingly divergent measures, with the VSL being 10-20 times higher than the HK. Both the absence of common theoretical underpinnings as well as the very different empirical settings in which the two values are calculated complicate any comparison exercise between the HK and VSL.

We have shown that is nonetheless possible to address both issues by relying on a unique and generic human capital problem to analytically compute and structurally estimate the theoretical VSL and HK values. We have also introduced a third method as a useful benchmark that addresses the indivisibility, non-marketability and ethical issues in life valuation and reflects the maximum amount an agent would be willing to pay to save himself from instantaneous and certain death (GPV). The willingness to pay to avoid changes in death risk, as well as the three closed-form for the life values were estimated jointly using a common structural econometric model and data set. This approach thus provided direct comparability as well as a unique opportunity to identify the role of the preferences, distributional and technological parameters on life valuations.

Our main findings can be summarized as follows. First, we validated the relevance of reduced-form estimates with a GPV value of 447 K\$, close to the HK value of 421 K\$, both of which are much lower than the VSL of 8.35 M\$. Second, we confirmed the standard economic intuition that the willingness to pay to avert death risk is increasing, but strongly concave and finite in mortality exposure. Allowing for a more general model with endogenous sickness and death intensities as well as source-dependent risk aversion only reaffirmed our findings. The large HK-VSL gaps are therefore *not* an artefact of segmented theoretical and empirical concepts.

Two potential explanations justify the wide disparities between the VSL and other measures. First, as famously pointed out by Schelling (1968), the VSL should be interpreted as an *aggregate* willingness to pay for infinitesimal changes in the mortality risk affecting an entire population. Conversely, the Human Capital and the Gunpoint values measure a market- and individual-based willingness to pay to avoid a large change in death risk (i.e. life versus certain death) that affects a single individual. There is therefore no *ex-ante* reason why the Statistical Life and other values should be equal.

However, our theoretical results helped clarify this ambiguity by highlighting the close linkages between the VSL and the other valuations via the willingness to pay. We also accounted for aggregation in formally showing that the empirical VSL is indeed a collective WTP, but that it will under-estimate the marginal rate of substitution captured by the theoretical VSL. Moreover, our empirical estimates showed that the extent of this bias is small when population size is large. Equivalently, the aggregate WTP versus individual MWTP explanation for the large VSL does not rationalize the large gaps with the other life values.

Second, we formally showed and provided empirical evidence that these differences are related to the strong curvature and finiteness of the WTP. In particular, the theoretical VSL is a linear projection from the marginal willingness to pay, whereas the empirical VSL is a local approximation to that MWTP. When the WTP is strongly concave, both theoretical and empirical VSL will strongly overestimate the limiting willingness to pay that corresponds to the Gunpoint Value. The empirical similarities between the HK and GPV values relate to the close theoretical parallels in the measured object. The HK computes the net present value of the foregone dividend stream associated with human capital (i.e. income, minus investment costs). The GPV measures the NPV of the foregone utility stream associated with living. The homogeneity properties entail that the latter is also the NPV of the foregone consumption above minimal subsistence requirements.

We concluded by reiterating Schelling (1968)'s warning that the VSL must not be interpreted as a value of a human value, but should remain employed in instances for which is was specifically designed. Whereas it is fully adequate for gauging an aggregate willingness to collectively pay for unidentified small reductions in mortality affecting and paid for by large populations, it produces significant errors when linearly integrated to value a given human life. Methods such as the HK or the GPV abstract from integrating marginal values and calculate unit life values instead. These approaches appear better suited when identified life values are required (e.g. in wrongful death litigation, curative vs terminal care decisions).

# References

- Adler, Matthew D., James K. Hammitt, and Nicolas Treich (2014) 'The social value of mortality risk reduction: VSL versus the social welfare function approach.' *Journal of Health Economics* 35, 82 – 93
- Aldy, Joseph E., and Seamus J. Smyth (2014) 'Heterogeneity in the value of life.' NBER Working Paper 20206, National Bureau of Economic Research, 1050 Massachusetts Avenue Cambridge, MA 02138, June
- Aldy, Joseph E., and W. Kip Viscusi (2007) 'Age differences in the value of statistical life: Revealed preference evidence.' Discussion paper 07-05, Resources for the Future, April
- Aldy, Joseph E., and W. Kip Viscusi (2008) 'Adjusting the value of a statistical life for age and cohort effects.' *Review of Economics and Statistics* 90(3), 573–581
- Andersson, Henrik, and Nicolas Treich (2011) 'The value of a statistical life.' In A Handbook of Transport Economics, ed. Andre de Palma, Robin Lindsey, Emile Quinet, and Roger Vickerman (Edward Elgar Publishing Inc.) chapter 17, pp. 396–424
- Arias, Elizabeth, Melonie Heron, and Jiaquan Xu (2017) 'United States life tables, 2013.' National Vital Statistics Report 66(3), 1–63
- Ashenfelter, Orley (2006) 'Measuring the value of a statistical life: Problems and prospects.' *Economic Journal* 116(510), C10–C23. Conference papers
- Becker, Gary S. (2007) 'Health as human capital: Synthesis and extensions.' Oxford Economic Papers 59, 379–410. Hicks Lecture delivered at Oxford University
- Becker, Gary S., Tomas J. Philipson, and Rodrigo R. Soares (2005) 'The quantity and quality of life and the evolution of world inequality.' *American Economic Review* 95(1), 277–291
- Bellavance, Francois, Georges Dionne, and Martin Lebeau (2009) 'The value of a statistical life: A meta-analysis with a mixed effects regression model.' *Journal of Health Economics* 28(2), 444–464

- Ben-Porath, Y. (1967) 'The production of human capital and the life cycle of earnings.' Journal of Political Economy 75(4), 352 – 365
- Blanchard, Olivier J. (1985) 'Debt, deficits and finite horizons.' Journal of Political Economy 93(2), 223–247
- Bodie, Zvi, Robert C Merton, and William F Samuelson (1992) 'Labor supply flexibility and portfolio choice in a life cycle model.' *Journal of Economic Dynamics and Control* 16(3-4), 427–449
- Carroll, Christopher D. (2001) 'A theory of the consumption function, with and without liquidity constraints.' *Journal of Economic Perspectives* 15(3), 23 45
- Carroll, Christopher D., Misuzu Otsuka, and Jiri Slacalek (2011) 'How large are housing and financial wealth effects? a new approach.' *Journal of Money, Credit, and Banking* 43(1), 55 – 79
- Conley, Bryan C. (1976) 'The value of human life in the demand for safety.' American Economic Review 66(1), 45 – 55
- Córdoba, Juan Carlos, and Marla Ripoll (2017) 'Risk aversion and the value of life.' *Review of Economic Studies* 84(4), 1472–1509
- De Nardi, Mariacristina, Eric French, and John Bailey Jones (2009) 'Life expectancy and old age savings.' *American Economic Review* 99(2), 110–115
- Doucouliagos, Hristos, T.D. Stanley, and W. Kip Viscusi (2014) 'Publication selection and the income elasticity of the value of a statistical life.' *Journal of Health Economics* 33(0), 67 – 75
- Drèze, Jacques H. (1962) 'L'utilité sociale d'une vie humaine.' Revue Française de Recherche Opérationnelle 23(6), 93–118
- Duffie, Darrell, and Larry G. Epstein (1992) 'Asset pricing with stochastic differential utility.' *Review of Financial Studies* 5(3), 411–436
- Ehrlich, Isaac, and Hiroyuki Chuma (1990) 'A model of the demand for longevity and the value of life extension.' *Journal of Political Economy* 98(4), 761–782

- Epstein, Larry G., and Stanley E. Zin (1989) 'Substitution, risk aversion and the temporal behavior of consumption and asset returns: A theoretical framework.' *Econometrica* 57(4), 937–969
- (1991) 'Substitution, risk aversion and the temporal behavior of consumption and asset returns: An empirical analysis.' *Journal of Political Economy* 99(2), 263–268
- French, Eric, and John Bailey Jones (2011) 'The effects of health insurance and selfinsurance on retirement behavior.' *Econometrica* 79(3), 693–732
- Friend, Irvin, and Marshall E. Blume (1975) 'The demand for risky assets.' American Economic Review 65, 900–922
- Grossman, Michael (1972) 'On the concept of health capital and the demand for health.' Journal of Political Economy 80(2), 223–255
- Gruber, Jonathan (2013) 'A tax-based estimate of the elasticity of intertemporal substitution.' Quarterly Journal of Finance 3(1), 1-20
- Guo, Sheng (2010) 'The superior measure of PSID consumption: An update.' *Economics* Letters 108(3), 253 – 256
- Hakansson, Nils H. (1969) 'Optimal investment and consumption strategies under risk, an uncertain lifetime, and insurance.' *International Economic Review* 10(3), 443–466
- Hall, Robert E., and Charles I. Jones (2007) 'The value of life and the rise in health spending.' *Quarterly Journal of Economics* 122(1), 39–72
- Hammitt, James K., and Nicolas Treich (2007) 'Statistical vs. identified lives in benefitcost analysis.' Journal of Risk and Uncertainty 35(1), 45 – 66
- Heckman, James J. (1976) 'A life-cycle model of earnings, learning, and consumption.' Journal of Political Economy 84(4), S11 – 44
- Hicks, John (1946) Value and Capital: An Inquiry Into Some Fundamental Principles of Economic Theory, second ed. (London: Clarendon Press)
- Hubbard, R. Glenn, Jonathan Skinner, and Stephen P. Zeldes (1994) 'Expanding the life-cycle model: Precautionary saving and public policy.' American Economic Review 84(2), 174 – 179

- \_ (1995) 'Precautionary saving and social insurance.' Journal of Political Economy 103(2), 360 399
- Huggett, Mark, and Greg Kaplan (2013) 'The money value of a man.' Working Paper 238, Griswold Center for Economic Policy Studies, June
- (2016) 'How large is the stock component of human capital?' Review of Economic Dynamics 22, 21 – 51
- Hugonnier, Julien, Florian Pelgrin, and Pascal St-Amour (2013) 'Health and (other) asset holdings.' *The Review of Economic Studies* 80(2), 663–710
- Hugonnier, Julien, Florian Pelgrin, and Pascal St-Amour (2017) 'Closing down the shop: Optimal health and wealth dynamics near the end of life.' Research Paper 17-11, Swiss Finance Institute, February
- Jena, Anupam, Casey Mulligan, Tomas J. Philipson, and Eric Sun (2009) 'The value of life in general equilibrium.' Working paper 14157, National Bureau of Economic Research, July
- Jones, Charles I. (2016) 'Life and growth.' Journal of Political Economy 124(2), 539 578
- Landefeld, J. Steven, and Eugene P. Seskin (1982) 'The economic value of life: Linking theory to practice.' American Journal of Public Health 72, 555–566
- Mankiw, Gregory N., and Stephen P. Zeldes (1991) 'The consumption of stockholders and non-stockholders.' *Journal of Financial Economics* 29(1), 97–112
- Murphy, Kevin M., and Robert H. Topel (2006) 'The value of health and longevity.' Journal of Political Economy 114(5), 871–904
- Petty, Sir William (1691) Political arithmetick, or a discourse concerning the extent and values of lands, people, buildings, etc (London: Robert Caluel)
- Philipson, Tomas J., Gary Becker, Dana Goldman, and Kevin M. Murphy (2010) 'Terminal care and the value of life near its end.' Working paper 15649, National Bureau of Economic Research

- Pratt, John W., and Richard J. Zeckhauser (1996) 'Willingness to pay and the distribution of risk and wealth.' *Journal of Political Economy* 104(4), 747 – 763
- Robinson, Lisa A., and James K. Hammitt (2016) 'Valuing reductions in fatal illness risks: Implications of recent research.' *Health Economics* 25(8), 1039 – 1052
- Schelling, Thomas C. (1968) 'The life you save may be your own.' In Problems in Public Expenditure Analysis: Papers Presented at a Conference of Experts Held Sept. 15-16, 1966, ed. Samuel B. Chase (Washington DC: Brookings Institution) pp. 127–162
- Shogren, Jason F., and Tommy Stamland (2002) 'Skill and the value of life.' Journal of Political Economy 110(5), 1168 – 1173
- Skinner, Jonathan (1987) 'A superior measure of consumption from the Panel Study of Income Dynamics.' *Economics Letters* 23(2), 213 – 216
- Skinner, Jonathan (2007) 'Are you sure you're saving enough for retirement?' Journal of Economic Perspectives 21(3), 59 – 80
- Sunstein, Cass R. (2013) 'The value of a statistical life: Some clarifications and puzzles.' Journal of Benefit-Cost Analysis 4(2), 237 – 261
- U.S. Census Bureau (2017) 'Poverty thresholds.' http://www.census.gov/data/tables/timeseries/demo/income-poverty/historical-poverty-thresholds.html
- U.S. Department of Transportation (2016) 'Revised departmental guidance on valuation of a statistical life in economic analysis.' https://www.transportation.gov/officepolicy/transportation-policy/revised-departmental-guidance-on-valuation-of-astatistical-life-in-economic-analysis
- U.S. Environmental Protection Agency (2017) 'What value of statistical life does EPA use?' https://www.epa.gov/environmental-economics/mortality-risk-valuation
- Viscusi, W. Kip (2010) 'The heterogeneity of the value of statistical life: Introduction and overview.' Journal of Risk and Uncertainty 40(1), 1 – 13
- Yaari, M. (1965) 'Uncertain lifetime, life insurance and the theory of the consumer.' *Review of Economic Studies* 52, 137–150

Yogo, Motohiro (2016) 'Portfolio choice in retirement: Health risk and the demand for annuities, housing, and risky assets.' Journal of Monetary Economics 80, 17–34

# A Figures





Notes: Reproduced and adapted from Andersson and Treich (2011, Fig. 17.1, p. 398). Indifference curves for indirect utility (2) is solid blue line.  $v_s$ : Theoretical Value of Statistical Life in (8a) is the MRS between life and wealth, i.e. the slope of tangent, i.e. dashed red line and equal to distance [a,d].

Figure 2: Willingness to pay and life valuations



Notes:  $\Delta$  is change in the probability of death from base exposure  $\mathcal{P}_0$ .  $v(\Delta)$ : Willingness to pay to avoid  $\Delta$  is solid blue line.  $v_s = v'(0)$ : Theoretical Value of Statistical Life in (8b) is slope of tangent, i.e. dashed red line and equal to distance [a,f].  $v_s^e = v(\Delta)/\Delta$ : Empirical Value of Statistical Life in (9) is slope of dashed-dotted green line and equal to distance [b,e].  $v_g = \sup_{\Delta}(v)$ : Gunpoint Value of Life in (10) is equal to distance [c,d].

Figure 3: Estimated WTP, HK, VSL and GPV Values of life (in M\$)



Notes: At estimated parameter values, for mean wealth and health levels.  $v(W, H, \lambda_m, \Delta)$  (blue solid line) is the willingness to pay to avoid an increase of  $\Delta$  in exogenous death intensity  $\lambda_m$ ;  $v_h(H, \lambda_m)$  (magenta dashed) is the Human Capital value of life;  $v_g(W, H)$  (black dashed-dotted) is the Gunpoint value of life;  $v_s(W, H, \lambda_m)$  is the Value of statistical life and the slope of the dashed red tangent evaluated at  $\Delta = 0$ .

# **B** Proofs

#### B.1 Theorem 1

The benchmark human capital model of Section 3 is a special case of the one considered in Hugonnier et al. (2013). In particular, the death and depreciation intensities are constant at  $\lambda_m$ ,  $\lambda_s$  (corresponding to their order-0 solutions) and the source-dependent risk aversion is abstracted from (i.e.  $\gamma_s = \gamma_m = 0$ ). Imposing these restrictions in Hugonnier et al. (2013, Proposition 1, Theorem 1) yields the the optimal solution in (22).

#### B.2 Proposition 1

The proof follows from Hugonnier et al. (2013, Prop. 1) which computes the value of the human capital P(H) from

$$P(H) = E_t \int_t^\infty m_{t,\tau} \left[\beta H_\tau^* - I_\tau^*\right] \mathrm{d}\tau,$$
  
= BH.

Straightforward calculations adapt this result to a stochastic horizon  $T^m$  and include the fixed income component y in income (12).

#### B.3 Proposition 2

Combining the Hicksian EV (6) with the indirect utility (21a) and using the linearity of the net total wealth in (19) reveals that the WTP v solves:

$$\Theta(\lambda_m^*)N(W,H) = \Theta(\lambda_m)N(W-v,H)$$
$$= \Theta(\lambda_m)\left[N(W,H) - v\right]$$

where we have set  $\lambda_m^* = \lambda_m + \Delta$ . The WTP  $v = v(W, H, \lambda_m, \Delta)$  is solved directly as in (26).

Next, by the properties of the marginal value of net total wealth,  $\Theta(\lambda_m^*)$  in (23) is monotone decreasing and convex in  $\Delta$ . It follows directly that the WTP

$$v(W, H, \lambda_m, \Delta) = \left[1 - \frac{\Theta(\lambda_m^*)}{\Theta(\lambda_m)}\right] N(W, H)$$

is monotone increasing and concave in  $\Delta$ . To compute its bounds, two cases must be considered:

1. For  $0 < \varepsilon < 1$ , the MPC in (17a) is monotone decreasing and is no longer positive beyond an upper bound given by:

$$\lambda_m^* = \lambda_m + \Delta < \bar{\lambda}_m = \left(\frac{\varepsilon}{1-\varepsilon}\right)\rho + \left(r + \frac{\theta^2}{2\gamma}\right)$$

Admissibility  $\mathcal{A}_m$  therefore requires  $\Delta < \overline{\Delta} = \overline{\lambda}_m - \lambda_m$  for the transversality condition (17a) to be verified. The supremum of the WTP is then  $v(W, H, \lambda_m, \overline{\Delta}) = N(W, H)$ .

2. For  $\varepsilon > 1$ , the MPC is monotone increasing and transversality is always verified. Consequently, the WTP is well-defined over the domain  $\Delta \ge -\lambda_m$ . It follows that:

$$\lim_{\Delta \to \infty} \Theta(\lambda_m + \Delta) = 0$$
$$\lim_{\Delta \to \infty} v(W, H, \lambda_m, \Delta) = N(W, H)$$

i.e. the willingness to pay asymptotically converges to net total wealth as stated in (27b).

#### B.4 Proposition 3

By the VSL definition (8a) and the properties of the Poisson death process (18):

$$v_s = \frac{-V_{\lambda_m}(W, H, \lambda_m)}{V_W(W, H, \lambda_m)}$$

From the properties of the welfare function (21a), we have that  $V_{\lambda_m} = \Theta'(\lambda_m)N(W, H)$ , whereas  $V_W = \Theta(\lambda_m)$ . Substituting for  $\Theta$  in (21b) yields the VSL in (28).

### B.5 Lemma 1

A higher likelihood of death of  $\Delta$  over a time interval of  $s \in [0, T]$  corresponds to an increase in the endowed intensity to  $\lambda_m^*(\Delta) > \lambda_m$ :

$$\Delta = \Pr\left[T_m \le T \mid \lambda_m^*\right] - \Pr\left[T_m \le T \mid \lambda_m\right],$$

Observing from (1) that:

$$\Pr\left[T_m \le T \mid \lambda\right] = 1 - E\left[e^{-\int_0^T \lambda \mathrm{d}s}\right] = 1 - e^{-T\lambda},$$

and substituting solves for  $\lambda_m^*$  reveals that the latter as stated in (31).

### B.6 Proposition 4

Combining the Hicksian EV (10) with the indirect utility (21a) and the net total wealth in (19) reveals that the WTP v solves:

$$V^{m} \equiv 0 = \Theta(\lambda_{m})N(W - v_{g}, H)$$
$$= \Theta(\lambda_{m})[N(W, H) - v_{g}]$$

Solving for  $v_g$  reveals that it is as stated in (32). Because net total wealth is independent of the preference parameters  $(\varepsilon, \gamma, \rho)$ , so is the Gunpoint Value.

# C Tables

## C.1 Data

	Model	Mean	Std. dev.	Min	Max
Health	H	2,85	0,80	1	4
Wealth	W	38  685	$122 \ 024$	0	$1 \ 430 \ 000$
Consumption	c	9 835	11  799	$1,\!05$	335  781
Risky holdings	$\pi$	20  636	81 741	0	$1 \ 367 \ 500$
Insurance	x	247	718	0	17  754
Health investment	Ι	721	2586	0	$107 \ 438$
Income	Y	21 838	37063	0	$1 \ 597 \ 869$
Age	t	45	16	16	100

### Table 1: PSID data statistics

*Notes:* Statistics in 2013 \$ for PSID data used in estimation (8 378 observations). Scaling for self-reported health is 1.0 (Poor), 1.75 (Fair), 2.50 (Good), 3.25 (Very good) and 4.0 (Excellent).

	Wealth quintiles					
Health	1	2	3	4	5	
		a. Wealth $W_i$ (\$)				
Poor	0	70	$1 \ 139$	10 357	136 209	
Fair	0	71	1  109	10  861	$188\ 044$	
Good	0	86	$1\ 214$	$11\ 207$	$160 \ 925$	
Very Good	0	90	$1 \ 282$	$11 \ 654$	178  580	
Excellent	0	88	$1 \ 315$	$11 \ 974$	$214 \ 106$	
		b. Co	onsumpti	on $c_j$ (\$)		
Poor	3 943	3 859	6 216	$10\ 473$	18 226	
Fair	4 724	5  702	$9\ 256$	$13 \ 491$	$15 \ 610$	
Good	6 459	$5\ 742$	9 205	$12 \ 457$	$17 \ 109$	
Very Good	5 684	5582	9 442	11 812	15  702	
Excellent	6 177	$5\ 616$	$10 \ 117$	11 575	$17 \ 465$	
D		с.	Stocks 7	$\pi_j$ (\$)	00 750	
Poor		0	83	1 402	39 752	
Fair		1	107	2 811	100 461	
Good		4	143	3 299	82 499	
Very Good		3	110	3 673	101 223	
Excellent	0	3	116	3 627	125 934	
	d Insurance $r_{i}$ (\$)					
Poor	50	142	123	304	230	
Fair	83	134	162	320	537	
Good	132	104	268	335	512	
Very Good	106	64	209	316	483	
Excellent	108	87	240	314	455	
	e. Investment $I_j$ (\$)					
Poor	783	792	852	$2 \ 021$	$4 \ 447$	
Fair	538	762	777	$1 \ 711$	2969	
Good	347	482	623	1 219	$1 \ 352$	
Very Good	250	318	422	639	$1 \ 070$	
Excellent	360	327	488	532	861	

 Table 2: PSID data statistics (cont'd)

Notes: Statistics in 2013  $\$  for PSID data used in estimation. Means per quintiles of wealth and per health status

# C.2 Benchmark model

Parameter	Value	Parameter	Value				
a. Law of motion health (11)							
lpha	0.6843	$\delta$	0.0125				
	(0.3720)		(0.0060)				
$\phi$	$0.0136^{c}$						
b. Sickness and death intensities							
$\lambda_s$	0.0347	$\lambda_m$	0.0283				
	(0.0108)		(0.0089)				
c. Income $(12)$ and wealth $(13)$							
y	0.0120	$\beta$	0.0092				
	(0.0049)		(0.0044)				
$\mu$	$0.108^{c}$	r	$0.048^{c}$				
$\sigma_S$	$0.20^{c}$						
d. Preferences (14)							
$\gamma$	2.8953	ε	1.2416				
·	(1.4497)		(0.3724)				
$a^c$	0.0140	$ ho^c$	0.0500				

Table 3: Estimated and calibrated structural parameter values, benchmark model

Notes: Estimated structural parameters (standard errors in parentheses); c: calibrated parameters. Econometric model (34), estimated by ML, subject to the regularity conditions (17).

Health level	Wealth quintile						
	1	2	3	4	5		
		a. Human Capital $v_b(W, H, \lambda_m)$ in (24)					
Poor	249 532						
Fair	318 865						
Good	388 198						
Very Good			457 531				
Excellent	526 864						
All							
- mean			420 729				
- median	457 731						
	b. Value of Statistical Life $v_s(W, H, \lambda_m)$ in (28)						
Poor	2 167 573	$2\ 168\ 877$	$2\ 188\ 829$	$2 \ 360 \ 907$	$4\ 710\ 118$		
Fair	4 379 551	$4 \ 380 \ 874$	$4 \ 400 \ 253$	$4\ 582\ 287$	$7\ 889\ 684$		
Good	6 591 529	6 593 136	$6\ 614\ 190$	$6\ 800\ 733$	$9\ 595\ 444$		
Very Good	8 803 507	8 805 188	$8\ 827\ 429$	$9\ 021\ 052$	$12 \ 136 \ 981$		
Excellent	11 015 485	11 017 133	$11\ 040\ 023$	$11\ 238\ 999$	$15\ 012\ 108$		
All							
- mean	8 351 519						
- median	8 803 507						
	c. Gunpoint Value $v_g(W, H)$ in (32)						
Poor	116 121	$116 \ 191$	$117 \ 259$	$126\ 478$	252 $329$		
Fair	234 620	234 691	235 729	$245 \ 481$	$422 \ 664$		
Good	353 120	$353 \ 206$	$354 \ 334$	$364 \ 327$	$514 \ 045$		
Very Good	471 619	471  709	472  901	$483\ 274$	650  199		
Excellent	590 119	$590\ 207$	$591 \ 433$	$602 \ 093$	804 225		
All							
- mean	$447 \ 405$						
- median			$471 \ 619$				

Table 4: Estimated Values of Life (in \$)

*Notes:* Averages of individual values in the PSID sample, computed at estimated parameter values, multiplied by 1 M\$ to correct for scaling used in estimation.

# D Data

The data construction follows the procedure in Hugonnier et al. (2013). We rely on a sample of 8,378 U.S. individuals obtained by using the 2013 wave of the Institute for Social Research's Panel Study of Income Dynamics (PSID, http://psidonline.isr.umich.edu/). All nominal variables in per-capita values (i.e., household values divided by household size) and scaled by  $10^{-6}$  for the estimation. The agents' wealth and health are constructed as follows:

- **Health**  $H_j$  Values of 1.0 (Poor health), 1.75 (Fair), 2.5 (Good), 3.25 (Very good) and 4.0 (Excellent) are ascribed to the self-reported health variable of the household head.
- Wealth  $W_j$  Financial wealth is defined as risky (i.e. stocks in publicly held corporations, mutual funds, investment trusts, private annuities, IRA's or pension plans) plus riskless (i.e. checking accounts plus bonds plus remaining IRA's and pension assets) assets.

The dependent variables are the observed portfolios, consumption, health expenditure and health insurance and are constructed as follows:

**Portfolio**  $\pi_j$  Money value of financial wealth held in risky assets.

- **Consumption**  $c_j$  Inferred from the food, utility and transportation expenditures that are recorded in PSID, using the Skinner (1987) method with the updated shares of Guo (2010).
- Health expenditures  $I_j$  Out-of-pocket spending on hospital, nursing home, doctor, outpatient surgery, dental expenditures, prescriptions in-home medical care.
- Health insurance  $x_j$  Spending on health insurance premium.